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ABSTRACT 
 
Chronic lymphocytic leukemia (CLL) is the most frequent type of B cell leukemia 
in adults. Treatment options against this incurable disease have continually been 
expanding with strategies using specific antibodies, inhibitors and individualized 
adaptive immunotherapy. However, none of these approaches is curative and 
devoid of adverse effects. In this preclinical ex vivo study, a novel therapeutic 
approach has been developed that uses B cell-specific antibodies coupled with 
antigens (antigen-armed antibodies, AgAbs) derived from the Epstein-Barr virus 
(EBV). The breadth of the immunogenic epitope repertoire within the coupled 
antigen is a critical factor for the immune response amplitude as it determines 
the potential number and diversity of memory T cell clones that can be 
reactivated. Along this line, a strongly immunogenic latent EBV antigen named 
EBNA3C was fragmented into large segments and conjugated to the antibody 
vehicles. Application of these antibody conjugates to leukocytes isolated from 
treatment-naïve CLL patients led to an efficient expansion of CD4+ T cells that 
recognized EBNA3C in all tested cases. Moreover, CLL cells pulsed with EBNA3C-
AgAbs induced specific responses of these T cells with widely varying intensities 
across the patient population. Interestingly, a large proportion of the EBV-
specific T cells consisted of highly efficient cytotoxic T lymphocytes (CTLs) that 
eliminated CLL cells loaded with EBNA3C through the granzyme B 
(GrB)/perforin-mediated pathway. The encouraging results from this study 
demonstrate the potential of AgAbs to redirect endogenous CD4+ CTLs against 
CLL cells loaded with EBV antigens in a high percentage of patients, and 
warrants the inception of clinical trials. 
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ZUSAMMENFASSUNG 
 
Die chronische lymphatische Leukämie (CLL) ist die am weitesten verbreitete B-
Zellleukämie bei Erwachsenen. Behandlungsmöglichkeiten dieser unheilbaren 
Krankheit sind kontinuierlich erweitert worden mit dem Einsatz von 
spezifischen Antikörpern, Inhibitoren und individualisierter, adaptiver 
Immuntherapie. Keiner dieser Ansätze ist jedoch kurativ und frei von 
Nebenwirkungen. In dieser präklinischen ex vivo Studie wurde ein neuartiger 
therapeutischer Ansatz entwickelt, der B-Zell-spezifische Antikörper gekoppelt 
mit Antigenen (engl.: antigen-armed antibodies, AgAbs) des Epstein-Barr Virus 
(EBV) einsetzt. Der Umfang an immunogenen Epitopen innerhalb des Antigens 
ist ein kritischer Faktor für die Stärke der Immunantwort, da dieser die 
potentielle Anzahl und Diversität an reaktivierbaren T-Zellgedächtniszellklonen 
bestimmt. Ein stark immunogenes, latentes EBV-Antigen, genannt EBNA3C, 
wurde in diesem Zusammenhang in große Segmente fragmentiert und zu den 
Antikörpervehikeln konjugiert. Die Anwendung dieser Antikörperkonjugate auf 
Leukozyten, die aus behandlungsnaiven CLL-Patienten isoliert wurden, führte 
zur effizienten Expansion von EBNA3C-spezifischen CD4+ T-Zellen in allen 
getesteten Fällen. Zudem induzierten CLL-Zellen, die mit EBNA3C-AgAbs pulsiert 
wurden, spezifische T-Zellenantworten mit stark wechselnden Intensitäten in 
der Patientenpopulation. Interessanterweise bestand ein großer Anteil der EBV-
spezifischen T-Zellen aus hocheffizienten, zytotoxische T-Lymphozyten (engl.: 
cytotoxic T lymphocyte, CTLs), die EBNA3C-beladene CLL-Zellen über den 
Granzym B (GrB)/Perforin-vermittelten Signalweg eliminierten. Die 
vielversprechenden Ergebnisse dieser Studie verdeutlichen das Potential der 
AgAbs, endogene CD4+ CTLs gegen EBV-Antigen-beladene CLL-Zellen in einem 
hohen Prozentsatz der Patienten umzulenken, was einen Anstoß für klinische 
Studien liefert. 
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1. INTRODUCTION 
 
Immunotherapy has become a clinically validated strategy to combat various 
types of cancer. Unlike standard aggressive and indiscriminate regimen, 
immunotherapeutic strategies use the immune system to recognize and 
eliminate tumors. Novel methods are on the rise including recombinant 
antibodies, adoptive cellular immunotherapy, immune checkpoint blockade, 
cancer vaccines, and oncolytic viruses. Treatment of chronic lymphocytic 
leukemia (CLL) has highly improved through the introduction of CD20-directed 
antibodies and checkpoint inhibitor blockers in combination with conventional 
chemotherapy. Adoptive transfer of ex vivo modified and expanded chimeric 
antigen receptor (CAR) T cells has shown dramatic potential in therapy for 
relapsed CLL patients, however, accompanied by severe side effects and great 
costs. Inevitably, novel anti-tumor therapeutics that selectively target cancerous 
cells, avoid drug resistances and go along with economical fast track production 
are urgently needed. In this work, antigen-armed antibodies (AgAbs) are 
reported as a promising treatment regimen for CLL. Our AgAbs include antigens 
of the ubiquitous Epstein-Barr virus (EBV). The antibody compartment acts as a 
vector to shuttle antigen directly into CLL cells to induce cytolytic antigen-
specific CD4+ T cell responses. The use of long antigenic attachments with 
numerous CD4+ T cell epitopes enlarges the breadth of potential patient-specific 
immune responses. Thereby, patient-derived cytolytic EBV-specific CD4+ T cells 
were activated, expanded, and redirected onto autologous primary CLL cells ex 
vivo. 
 
 
1.1. Chronic lymphocytic leukemia 
 
1.1.1. Incidence, epidemiology, classification, origin and diagnosis 
 
CLL is the most frequent leukemia in the Western world. The incidence is 
currently at 4.2:100 000/year with new cases increasing to > 30:100 000/year at 
an age of > 80 years. The median age at the time of diagnosis is 72 years [1]. 
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According to the World Health Organization (WHO) classification, CLL is a 
disease of mature B cell neoplasm, also known as B cell CLL, or B-CLL [2]. An 
uncontrolled clonal expansion of CD5+ B cells is characteristically observed in the 
peripheral blood and in the bone marrow of CLL patients [3]. These cells have 
high resistance to apoptosis and prolonged survival due to the overexpression of 
Bcl-2, an anti-apoptotic protein [3, 4]. It appears most likely that antigen-
experienced B cells from the marginal zone give rise to the emergence of CLL 
cells, with either unmutated or mutated immunoglobulin heavy chain variable 
(IGHV) status. However, it remains unclear at what stage(s) oncogenesis occurs 
and whether a single or multiple normal precursors are stimulated to evolve into 
CLL [5, 6]. CLL is mostly diagnosed through routine blood tests. Diagnosis 
requires the detection of a monoclonal population of > 5000 B cells/L in the 
peripheral blood for a period of at least 3 months. A bone marrow biopsy is often 
necessary to evaluate the neoplastic burden before the beginning of treatment 
[7]. 
 
 
1.1.2. Clinical staging 
 
Clinical staging of CLL exists in two widely accepted forms. Binet is most 
common in Europe and the United Kingdom [8]. Rai is frequently used in the 
United States [9]. The two systems are presented in the following section. Binet 
divides CLL into three different stages (Table 1). 
 
Table 1: Binet clinical staging system for CLL. 
Stage Definition Median survival [10] 
Binet A Enlarged lymphoid tissue in fewer than three areas. 
No anemia (Hb > 10.0 g/dL) or thrombocytopenia 
(platelets > 100 x 109/L). 
> 10 years 
Binet B Enlarged lymphoid tissue in three or more areas. No 
anemia (Hb > 10.0 g/dL) or thrombocytopenia 
(platelets > 100 x 109/L). 
> 8 years 
Binet C Enlarged lymph nodes or spleen. Anemia (Hb < 10.0 
g/dL) and/or thrombocytopenia (platelets > 100 x 
109/L). 
6.5 years 
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The other clinical system, Rai, comprises five stages (Table 2). 
 
Table 2: Rai clinical staging system for CLL . 
Stage Definition Median survival [10] 
Low risk > 10 years 
Rai 0 Lymphocytosis with more than 5,000 
lymphocytes/ɊL. No other physical signs, such as 
enlarged lymph nodes, spleen, liver. Normal counts of 
red blood cells and platelets. 
Intermediate risk > 8 years 
Rai I Lymphocytosis (> 15 x 109/L). Enlarged lymph nodes. 
No enlargement of spleen, liver. No anemia or 
thrombocytopenia. 
Rai II Lymphocytosis. Enlarged spleen, lymph nodes and/or 
enlarged liver with or without enlarged lymph nodes. 
No anemia or thrombocytopenia. 
High risk 6.5 years 
Rai III Lymphocytosis. Enlarged liver or enlarged spleen 
with or without enlarged lymph nodes. Anemia (Hb <  
11 g/dL). No thrombocytopenia. 
Rai IV Lymphocytosis. With or without enlarged lymph 
nodes, enlarged liver or spleen. Thrombocytopenia 
(platelets < 100 x 109/L) with or without anemia. 
 
Both staging systems only require physical examination, and are inexpensive 
since standard laboratory tests are sufficient for diagnosis. Additional prognostic 
information can be particularly collected at early stages of disease [7]. TP53 
deletion/mutation (5 – 10 % of CLL patients) predicts for very poor outcome 
(median survival: 2 – 3 years) [11, 12]. Deletion of 11q (18 % of CLL patients) is 
another marker that is associated with several adverse prognostic factors [13, 
14]. CLL patients with unmutated IGHV status (approx. 50 %) have unfavorable 
clinical outcomes with shorter overall survival and shorter time to treatment 
intervention [15, 16]. Expression of ZAP-70 (> 20%) and CD38 (> 30 %) seem to 
correlate with inferior clinical outcomes. Unlike unmutated IGHV, however, these 
markers do not seem to influence treatment modality [17, 18]. 
 
 
1.1.3. Current treatment 
 
CLL is a slowly progressing blood cancer type, which is rarely curable. Treatment 
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does usually have severe side effects. A therapy decision is based on the 
individual clinical picture and often only advised to patients with active 
symptoms such as cytopenia, lymphadenopathy, splenomegaly, hepatomegaly, 
and high lymphocyte doubling times [1]. Patients with an early, stable disease 
(Binet stage A and B without active disease; Rai stage 0-II without active disease) 
are monitored through routine checkups, which include blood cell counts and 
clinical examinations every 3 to 12 months. Chemotherapy for early-stage CLL 
patients does not result in a survival advantage [19]. CLL patients with advanced 
symptoms (Binet stage A and B with active disease, Binet stage C; Rai 0-II with 
active disease, Rai III-IV) require a treatment. For the assessment of an 
appropriate treatment, additional clinical features such as age, fitness, co-
morbidity, prognostic markers, and previous treatments need to be evaluated. 
The FCR (fludarabine, cyclophosphamide, rituximab) therapy protocol is the 
standard treatment modality for fit patients (physically fit without major health 
problems and normal renal function) without TP53 deletion/mutation. FCR 
includes chemotherapy with fludarabine and cyclophosphamide, and treatment 
with rituximab, which is an anti-CD20 monoclonal antibody (mAb). The standard 
first-line regimen has demonstrated improved overall survival (OS) [20]. Other 
purine analogues such as cladribine [21], or pentostatin [22] are similarly 
effective but unlikely to replace fludarabine in the FCR regimen. Bendamustine 
and rituximab (BR) may be an option for fit elderly patients with pervious 
history of infections since FCR is associated with higher risk for severe 
infections. However, BR is considered to translate into fewer complete 
remissions than FCR [23]. Patients with relevant comorbidity but without TP53 
deletion/mutation are given a combination of chlorambucil (Clb) plus an anti-
CD20 mAb (rituximab, ofatumumab or obinutuzumab) in a standard therapy, 
which has shown prolonged progression-free survival (PFS) compared to 
monotherapy [24, 25]. 
Patients with TP53 deletion/mutation often do not respond to conventional 
chemotherapy with fludarabine or FC, or show short progression-free survival 
after FCR therapy [20]. Hence, treatment with novel inhibitors such as ibrutinib ȋBruton’s tyrosine kinase inhibitorȌ [26], or idelalisib (PI3K inhibitor) plus 
rituximab [27] is recommended for this patient cohort in first-line and relapse 
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regimen. Fit patients with TP53 deletion/mutation may be treated with CLL-
pathway inhibitors in combination with allogeneic hematopoietic stem-cell 
transplantation (HSCT) [28]. The front-line treatment for CLL and small 
lymphocytic lymphoma (SLL) is summarized in Figure 1. 
 
 
Figure 1: Front-line treatment for CLL/SLL [1]. 
 
Treatment of relapse and refractory disease should only be initiated in 
symptomatic CLL. Asymptomatic patients with relapsed disease can be 
monitored without any therapy. If relapse or progression occurs in patients 
without TP53 deletion/mutation after 24 – 36 months from the start of initial 
chemoimmunotherapy, first-line therapy can often be repeated. Alternatively, 
(BR)/FCR B cell receptor (BCR) inhibitor (+/- R) can be administered. Patients 
with relapse within 24 – 36 months after chemoimmunotherapy should be given 
an alternative treatment, especially if the patient does not respond to any first-line therapy at all. Depending on the patient’s fitness, following options may be 
chosen: (1) Bcl-2 antagonist; (2) ibrutinib; (3) idelalisib; (4) BCR inhibitor (+/- 
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R) in combination with allogeneic HSCT [28]; (5) other chemotherapeutic agents 
should only be applied for patients without TP53 deletion/mutation. Treatment 
options for relapsed or refractory CLL/SLL treatment are summarized in Figure 
2.  
 
 
Figure 2: Relapse treatment for CLL/SLL [1]. 
 
1.1.4. Frontiers of anti-CD20 mAbs in the treatment of CLL 
 
The approval of rituximab, a humanized mAb targeting CD20 has revolutionized 
treatment strategies in B cell lymphoproliferative diseases [29-37]. Rituximab-
directed tumor killing is mediated through several mechanisms, including 
antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent 
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cytotoxicity (CDC), and/or direct induction of apoptosis. Additionally, anti-CD20 
mAbs can be used as delivery tools for shuttling radioisotopes, toxins, or other 
drugs into target cells [38-44]. The combinatorial FCR treatment has shown high 
response rates and improvement in OS. Yet, treatment efficacy with rituximab 
greatly depends on the tumor burden and subtype [45, 46], and rituximab-
induced effector cytotoxicity does not always eliminate all malignant B cells. 
Thus, many cases show resistance to rituximab or rituximab-containing 
combination therapy [20, 35, 36, 47-50]. Surviving B cells appear to acquire 
adaptive mechanisms to escape rituximab-mediated cytotoxicity through 
antigenic modulation. Interestingly, these cells are still able to express CD20 in 
many patients [33, 51]. Moreover, effector saturation or exhaustion by rituximab 
may jeopardize the treatment efficiency. Mechanisms such as CDC and NK cell-
mediated killing have been observed to be impaired, and rituximab-opsonized B 
cells are instead processed by an alternative pathway mediated by effector cells’ 
FcR. In this case, rituximab/CD20 complexes are removed from B cells and 
eventually absorbed by monocytes and/or macrophages (trogocytosis) [50]. 
Immune responses with significant clinical activity against CLL have often been 
exclusively achieved with dose escalation by factor six when compared with 
follicular lymphomas (FLs), which are relatively sensitive to rituximab [52-55]. 
This may additionally be caused by divergent sensitivity of various lymphoma 
cells, different consumption rates, antibody internalization, CD20 
downregulation, or receptor-coating efficiency of the antibody [20]. 
 
 
1.1.5. T cell dysfunction in CLL 
 
T cell dysfunction is observed in patients with advanced clinical staging of CLL. 
These malfunctions include an increased absolute number of CD4+ and CD8+ T 
cells [56], inversed CD4/CD8 ratios [57-59], altered cytokine production 
including interferon gamma (IFN-) and interleukin 4 (IL-4) [60, 61], which 
jointly are likely to explain the reduced T cell responses to antigenic stimulation 
in CLL [62, 63]. T cells in CLL patients also show structurally modified actin 
cytoskeletons caused by impaired F-actin polymerization. Consequently, 
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cytotoxic T lymphocytes (CTLs) are inhibited in releasing their granules due to a 
defective immune synapse formation with antigen-presenting cells (APCs). In 
addition, inhibited recruitment of regulatory proteins to the synapse was 
observed. A complementary effect in synapse dysfunction is mediated by CLL 
cells, which have poor APC function. Synapse formation is improved after the 
treatment of T cells and CLL cells with lenalidomide [64, 65]. The 
immunomodulatory drug, which is a synthetic derivative of thalidomide, has 
been shown to act on T cells via the B7-CD28 co-stimulatory pathway. A 
blockade of B7-CD28 by CTLA-4-Ig is partially overcome by direct induction of 
tyrosine phosphorylation of CD28, which leads to activation of downstream 
targets such as PI3K and NF-b [66]. Moreover, T cells in CLL subjects have been 
found to express an oligoclonal T cell receptor (TCR) V gene pattern [67-69], 
enhanced susceptibility to FasL-induced apoptosis [70], and declined expression 
of CD40L, -chain of TCRs, and CD28 [60, 61]. However, the exact mechanism 
that causes T cell dysfunction in CLL remains unclear. It is assumed that chronic 
T cell antigen stimulation in CLL is caused by a synergy of several 
aforementioned abnormalities. The impact of dysfunctional T cells in the 
pathogenesis and immunosuppression of CLL patients has not yet been 
elucidated. 
 
 
1.2. EBV classification, etiology, infection, and T cell responses 
 
EBV is an orally transmitted human γ-herpesvirus with a seroprevalence rate of 
more than 90 % in the adult human population worldwide [71]. This ubiquitous 
pathogen, also known as human herpesvirus 4 (HHV-4), carries a linear double 
stranded DNA genome that is 172 kbp in size. Etiologically, EBV is linked to 
numerous human tumors including Burkitt’s lymphoma ȋBLȌ, (odgkin’s 
lymphoma (HL), post-transplant lymphoproliferative disease (PTLD), 
nasopharyngeal carcinoma (NPC), extranodal T/NK cell lymphoma, 
leiomyosarcoma, and gastric carcinomas (GaCa) [72-74]. Primary infection with 
EBV mostly occurs during infancy and early childhood and is generally 
asymptomatic for most persons. Infection during adolescence or adulthood often 
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results in infectious mononucleosis (IM) owing to strong CD8+ T cell responses 
[75-77]. Initial replication of orally transmitted EBV starts in the oropharynx. 
Lytic replication is supported by extensive shedding of locally infiltrating B cells 
and squamous epithelial cells. B cells in oropharyngeal lymphoid tissues are 
growth-transformed (latency III) in the course of the spreading infection. The 
growth-transforming program is downregulated in some B cells, thereby moving 
into the memory B cell pool. Once the initial lytic replication is 
immunocontrolled, lifelong latent infection is established through viral 
persistence in memory B cells (latency 0). Occasionally, infected cells are able to 
switch from latent into lytic cycle within the oropharynx [78, 79]. Primary 
infection leads to activation of NK cells and large expansion of EBV-specific CD8+ 
T cells in the blood. EBV-specific CD4+ T cell subsets also substantially expand 
during primary infection with some clones reaching frequencies of 1 % of the 
peripheral CD4+ T cell epitope responses [80, 81]. Although EBV-specific T cell 
populations are greatly reduced during persistent infection, healthy EBV carriers 
cover the class II-restricted EBV epitope repertoire with up to 0.1 % of the 
overall CD4+ T cell pool [80]. The chronological order of infection is summarized 
in Figure 3. 
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Figure 3: EBV infection and persistence. EBV establishes primary infection in the squamous 
epithelium and possibly in local B cells. Virus is shed through lytic replication. B cells in local 
lymphoid tissues are growth-transformed (latency III) by EBV. Some of these B cells escape the 
immune recognition through downregulation of antigen expression thereby establishing a pool of 
latently infected memory B cells (latency 0), which circulate in the blood and oropharyngeal 
lymphoid tissue. Occasionally, latently infected memory B cells switch into the lytic mode 
whereby virions are replicated and shed into the oral epithelium, which may lead to infection and 
transformation of adjacent B cells. Primary EBV infection induces activation of NK cells and EBV-
specific CD8+ T cells. EBV-specific CD4+ T cells experience smaller expansion. At persistent 
infection, lower numbers of EBV-specific memory T cells are left in the blood. Blue arrows: 
transfer of virions. Black arrows: transition of infected cells. Gray arrows: immune response 
against infected cells. Lat 0: latency 0. Lat III: latency III. B: B cell (modified from [79]). 
 
In healthy virus carriers, EBV is constantly supervised and eliminated by anti-
viral immune responses, which include both CD4+ and CD8+ T cell effectors [82-
84]. The intensity and frequency of memory CD4+ and CD8+ T cell responses 
against latent and lytic antigens are summarized in Figure 4. 
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Figure 4: Response frequency of EBV-specific CD8+ T cells and CD4+ T cells against lytic and 
latent cycle antigens. Results have been compiled from > 30 EBV-infected Caucasian subjects 
(screened with EBV peptide libraries using IFN-γ ELISPOT assay in most cases). Arrow height: 
mean size of response. Arrow shading: frequency of response with dark orange for commonly 
seen responses ad lighter orange as rarely seen response. n.t., not tested (modified from [79]). 
 
A screening on peptide panels showed that three latent-cycle antigens, EBNA-1, -
2, and -3C, are each recognized by the majority of tested EBV-seropositive 
persons (65 – 75 %) through CD4+ T cell responses [85]. Furthermore, some 
isolated EBV-specific CD4+ T cell clones have been found to exert direct 
cytotoxicity against target cells presenting both lytic and latent EBV class II 
antigens [83, 86-96].  
 
 
1.3. Resistance of CLL cells to EBV-induced transformation 
 
EBV is not entangled in the pathogenesis of CLL. Moreover, CLL cells are 
refractory to EBV-induced immortalization in vitro [97]. Most CLL patients are 
EBV-positive and express CD21, which is necessary for EBV uptake. Binding of 
EBV to the receptor and virus entrance into the CLL cells have been reported to 
be functional. Yet, experimental infection of CLL cells with B95.8, a transforming 
EBV strain, has only shown fractional success with rare clones that were induced 
to proliferate [82, 98-101]. Along this line, it has been observed that EBNA 
antigens are not expressed by CLL cells. Unlike observations in transformed 
normal B cells, EBV-infected CLL cells do not express c-myc, cyclin D2, or pRb. 
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Additionally, p27, a cell cycle inhibitor, is not downregulated [102]. 
 
 
1.4. CD4+ CTLs 
 
Naïve CD4+ T cells can differentiate into several types of T helper (Th) cells. Their 
activation is induced in response to antigen presentation and cytokine secretion 
in the extracellular milieu [103]. Th cells play a critical role in the adaptive 
immunity by providing humoral immune responses and essentially regulating 
effector and memory CD8+ T cells, macrophages, and B cells. In contrast, CD8+ T 
cells classically convey direct immune responses. However, recent advances have 
challenged this conventional view by uncovering CD4+ CTLs in anti-viral and 
anti-tumor immunity [91, 104-121]. This phenomenon was initially highlighted 
in murine and human T cells in vitro [91, 122-129]. In this context, CD4+ CTLs are 
crucial for the control of chronic viral infections such as EBV [130], 
cytomegalovirus (CMV) [128], human immunodeficiency virus (HIV) [129], 
lymphocytic choriomeningitis virus (LCMV) as well as acute influenza virus 
infections [131, 132], and play a significant role in the pathogenesis of 
autoimmune diseases [133, 134]. 
Two major contact-dependent cytotoxic mechanisms have been observed in the 
immune response against certain viruses and tumor cells. First, several proteins 
of the tumor necrosis factor (TNF) family such as Fas ligand (FasL), TNF-Ƚ or 
TNF-related apoptosis-inducing ligand (TRAIL) have been proposed to possess 
cytolytic activities [135, 136]. Activation of extrinsic apoptosis signaling 
pathways can be induced in target cells through the interaction of these proteins 
with their cognate receptors. FasL/Fas receptor-mediated cytotoxicity, for 
instance, is triggered through the binding of FasL, an antigen expressed on the 
surface of CD4+ T cells, to the Fas receptor on the target cell surface [137]. 
Second, CD4+ T cell cytotoxicity can be mediated by the exocytosis of cytoplasmic 
granules [138], which are membrane-enveloped lysosomes [139].  Perforin and 
granzymes are the main components of these lysosomes [138, 139] that form a 
lipid bilayer with inserted lysosomal-associated membrane glycoproteins 
(LAMPs) including LAMP-1 (CD107a), LAMP-2 (CD107b), and LAMP-3 (CD63) 
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[140]. The released molecules can synergistically kill target cells. Perforin is a 
toxin that forms pores and disrupts target cell membranes. Granzymes are serine 
proteases with pro-apoptotic function mediated through the activation of target 
cell caspases, which eventually induce target cell death [104, 132, 141, 142]. 
Granzyme B (GrB) in particular, is an important component of the 
perforin/granzyme-induced cytotoxicity that cleaves caspase 3 in target cells 
[143, 144]. Additionally, GrB can act in a caspase-independent manner by 
modulating other intracellular target proteins such as Bid, inhibitor of apoptosis 
(IAP), endonuclease G (ENDOG), caspase-activated DNase (CAD), and enzymes 
involved in DNA repair [141, 145]. Lysosomal degranulation is triggered by 
antigenic stimulation of the cytotoxic effector cell. Thereby, cytolytic granules 
are transported towards the synapse formed between the effector and target cell 
through polarizing microtubules [138, 146]. Transient fusion between lysosomal 
and cellular membranes occurs, which allows secretion of cytolytic contents into 
the synapse. As a consequence, LAMPs erstwhile exclusive to the interior lipid 
bilayer of the lysosomal membrane, are now expressed on the cell surface [140, 
147]. This mechanism is schematically presented in Figure 5. 
 
 
 
 
 
 
 
 
 
Figure 5: Expression of CD107a on the cell surface of CD4+ CTLs upon activation and 
degranulation. CD107a is not detectable on the cell surface of resting CD4+ CTLs (left panel). 
Upon stimulation, lytic granules transiently fuse with the plasma membrane of effector T cells. 
Exocytosis of perforin/GrB-containing granules temporarily exposes CD107a to the T cell surface 
(right panel).  
 
Both of these direct cell-mediated cytotoxic pathways culminate in activating 
caspases and inducing apoptosis in target cells [110]. Having two distinct 
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cytotoxic effector mechanisms is advantageous for cytotoxic cells since they 
provide alternative killing routes in cases of dysfunctional pathways. Hence, it 
has been reported that perforin/GrB-mediated killing can compensate for the 
loss of FasL/Fas-mediated cytotoxicity [148]. Target cell lysis through 
perforin/granzyme-mediated cytotoxicity occurs from minutes up to a few hours 
whereas target cell apoptosis through the FasL/Fas receptor or TNF-Ƚ/TNF 
receptor pathway may take 12 – 24 hours [149-151]. Contribution of each of the 
two major contact-dependent cytotoxic mechanisms is still ambiguous in 
clinically relevant contexts regarding CTL-induced cell deaths. 
 
 
1.5. T cell-based immunotherapy 
 
Advances in T cell-based immunotherapy have shown great promise in the 
treatment of cancer patients, particularly through adoptive cell transfer [152]. T 
cells play an essential role in the graft-versus-leukemia (GVL) effect for patients 
resistant to chemotherapy and small-molecule drugs. Therefore, adoptive T cell 
therapy using tumor-infiltrating lymphocytes (TILs) has become an emerging 
treatment option for patients with metastatic melanoma. TILs, which consist of 
more than 90 % CD8+ T cells, were found to be restricted to unknown antigens, 
most likely CD8+ T cell epitopes from mutated self-proteins, also named neo-
antigens. Unfortunately, TILs cannot always be accessed for therapy, and 
expansion from tumor sample to sufficient cell material enriched in laboratory 
bioreactors remains a challenging task [153]. Furthermore, several studies have 
emphasized low chances of success in inducing HLA-dependent CTL responses 
against unmodified autologous CLL cells [154]. An elegant approach to overcome 
these barriers is the engineering of T cells with transduced tumor-associated 
antigen (TAA)-specific TCR genes. However, TAAs are mostly self-proteins with 
weak immunogenicity, and their TCRs typically show low avidity [155, 156]. In 
contrast, viral antigens are of non-self origin with characteristically high 
immunogenicity. Moreover, the EBV-specific T cell repertoire generally shows 
high avidity with strong direct effector function compared to TILs. To date, CAR 
T cells and bi-specific T cell engagers (BiTEs) are highly advanced therapeutic 
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concepts that are mostly investigated in clinical trials against hematologic 
malignancies. CAR T cell therapy consists of the adoptive transfer of genetically 
engineered T cells that express CARs on their cell membrane. In the treatment of 
acute lymphoblastic leukemia (ALL), anti-CD19 CAR T cells yielded a complete 
remission rate with up to 90 % [157]. However, broad application of CAR T cell 
therapy is challenged by the loss of target antigen observed in the treatment of 
ALL, off-target cytotoxicity against healthy tissue by CAR T cells, hostile tumor 
microenvironment, and cost-expensive industrialization [157]. In the treatment 
with BiTEs, the most commonly investigated molecule, blinatumomab, is a fusion 
protein that consists of two single-chain variable fragments (scFvs), which binds 
to tumor cells via CD19 receptors and to T cells via CD3 receptors. Concurrent 
engagement of target and effector cells induces polyclonal T cells to exert 
cytotoxic activity by secreting perforin and granzymes [158]. Blinatumomab is in 
clinical use for patients with relapsed/refractory ALL [159-163]. However, 
treatment with blinatumomab does not seem favorable in combination with 
global T cell defects in CLL. Along this line, BiTEs target the overall T cell 
population without selectively recruiting functionally intact T cell subsets. 
Moreover, T cell counts remained stable or slightly increased during and after 
treatment with blinatumomab [164]. Therefore, patients with significantly 
reduced T cell proportions will most likely not benefit from such treatment since 
extensive T cell expansion is not anticipated. Patients also need to rely on a 
continuous intravenous infusion due to the small molecular weight of BiTEs and 
rapid clearance from circulation [164]. Both immunotherapy approaches, CAR T 
and BiTE, are based on HLA-independent CTL responses. 
 
 
1.6. The concept of AgAb treatment 
 
Antigen-armed antibodies, or AgAbs, are chimeric fusion proteins that combine 
mAbs with immunogenic antigens (Figure 6a). The antibody compartment serves 
as a target vehicle that delivers the attached foreign antigen to APCs. The antigen 
is introduced into APCs through receptor-mediated endocytosis, which results in 
the presentation of CD4+ T cell epitopes on the HLA class II molecules. As a 
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result, CD4+ T cells specific to the conjugated antigen recognize the epitope-
presenting HLA class II molecules with their TCRs. The activated T cells may 
release cytokines and cytolytic compounds, which eventually leads to target cell 
lysis [165, 166]. The proposed mechanism is presented in Figure 6b. 
 
 
Figure 6: Principle of the AgAb treatment. (a) Simplified schematic representation of an AgAb 
molecule composed of four polypeptides - two light chains, and two heavy chains with antigenic 
peptides coupled to the C-termini. Dark grey: human CD-specific variable region. Light grey: 
mouse IgG2a constant region. Red: peptide antigen. (b) Proposed mechanism of target cell killing 
by AgAbs. AgAbs are applied onto target cells. Together with the shuttle antibody, antigenic 
peptides are internalized through receptor-mediated endocytosis, and HLA-II haplotype-
restricted epitopes are presented on the target cell surface. Epitope-restricted CD4+ T cell clones 
are activated, which induce cytokine secretion. Target cell killing is mediated through perforin 
and granzyme release. 
 
AgAbs may carry diverse antigens of viral and bacterial origin or even mutated 
oncogenes. This highlights the molecule as a promising immunotherapeutic 
agent. Along this line, DEC-205-expressing lymphoblastoid cell lines (LCLs) were 
effectively targeted by an anti-DEC-205 antibody conjugated with EBV antigens. 
The target cells were subsequently recognized by peptide-specific CD4+ T cells 
[167]. In 2015, Yu & Ilecka et al. demonstrated that Burkitt’s lymphoma cells 
pulsed with AgAbs were recognized and killed by EBV-specific CD4+ CTL clones 
derived from healthy donors. For this purpose, AgAbs directed against B cell 
surface receptor CD19, CD20, CD21, or CD22, with conjugated latent-cycle EBV 
peptides were used [168].  
(a) (b) 
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Moreover, AgAbs may serve as vaccines. Vaccination studies with antibody-
antigen conjugates have mainly been tested with dendritic cells. Therefore, viral 
or tumor antigens were shuttled into target cells using antibodies specific to 
DEC-205, Langerin or Clec9a. These vaccines elicited combined humoral and 
cellular immunity including primed IFN-γ secreting T cells, and induced antibody 
titers against the delivered antigens in immunized mice. T cell immunization was 
greatly enhanced relative to native control antibodies, or non-targeted antigen 
peptides [169-172].  
 
 
1.6.1. Expression of target molecules on B cells 
 
B cell differentiation occurs in multiple stages from precursor B lymphoblast to 
mature plasma cell. The progression of immunoglobulin (Ig) gene 
rearrangements is linked to the characteristic expression of surface receptors for 
each stage of development. The expression profile of cluster of differentiation 
(CD) proteins, a group of cell surface markers, differs throughout B cell 
development and can be used to identify and distinguish different stages of B cell 
differentiation [29]. Hence, markers preferentially expressed by post-early stage 
B cells such as CD19, CD20, CD21, and CD22 are potential targets for antibodies 
in immunotherapy. In contrast, targeting molecules expressed on hematopoietic 
stem cells (HSC), neurons or early-stage B cells may result in serious hematologic 
side effects and are not suitable targets for treatment. 
In the present study, CD19, CD20, CD21, and CD22 were chosen as B cell receptor 
targets. CD20 is a transmembrane phosphoprotein that is expressed on both 
immature and mature B cells [173, 174]. CD20 directly regulates transmembrane 
calcium conductance in B cells [175]. Rituximab was the first anti-CD20 antibody 
approved for the treatment of lymphoma [176, 177]. CD19 and CD21 are B cell 
surface receptors that are part of a signal transduction complex [178]. Co-
engagement of CD19/CD21 supports antigen processing in B cells [179]. Both 
molecules are biomarkers for B cells and follicular dendritic cells (FDCs) [180-
183]. However, FDCs were reported to lack HLA class II expression. Therefore, 
FDCs cannot stimulate CD4+ T cells [184]. CD19 is a transmembrane glycoprotein 
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that belongs to the Ig superfamily. Evidence exists that the receptor recruits 
cytoplasmic signaling proteins to the membrane either in an antigen-
independent manner or as a result of BCR engagement [180, 185, 186]. CD21, 
also known as complement C3d receptor, is expressed during immature and 
mature stages of B cell development [187, 188]. In addition, EBV is known to 
enter B cells through CD21 binding [189]. CD22, a highly restricted B cell marker, 
is a member of the Ig-like lectin family. As primary function, it negatively 
regulates BCR activation upon antigen stimulation [190-194].  
In vitro studies have demonstrated a variable degree of internalization of 
antibody-bound receptor complexes in each of the above-quoted molecules. Anti-
CD19 mAbs, for instance, are immediately internalized after binding to their 
cognate receptors [195, 196]. However, high CD21 expression may decrease 
internalization of anti-CD19 mAbs [195] while CD21-negative or low expressing 
cells rapidly internalized CD19 mAbs in clathrin-coated vesicles followed by 
lysosomal delivery. Transfection of Ramos cells with CD21 showed impaired 
uptake of anti-CD19 mAbs and lower cytotoxic effects of anti-CD19-drug 
conjugates. This may imply that CD21-negative tumor cells can be treated more 
efficiently with anti-CD19 mAbs [195]. As mentioned before, EBV utilizes CD21 
molecules for binding B cells, which is followed by internalization of the 
receptor-virus complex [189, 197]. In Raji cells, however, anti-CD21 mAbs were 
not sufficiently internalized resulting in low therapeutic efficacy with anti-CD21-
drug conjugates [195]. It is unclear whether impeded anti-CD21 uptake may 
correlate with high expression levels of CD19. CD22 undergoes constitutive 
internalization, which is mediated by clathrin [198]. Du et al. showed that their 
anti-CD22-drug conjugate composed of mAb and immunotoxin was internalized 
within 15 minutes. The consumption of anti-CD22-drug conjugates was high in 
number with two to three fold more molecules being internalized than CD22 
receptors detected on the cell surface, which implicates that CD22 is 
constitutively recycled to the cell surface. Hence, CD22 can serve as an attractive 
target for drug delivery [199]. In previous reports, CD20 internalization has also 
been detected after ligation with anti-CD20 mAb [200, 201]. Hereby, activatory 
and inhibitory Fcγ receptors ȋFcγRsȌ do not promote internalization of 
rituximab-ligated CD20, however, they augment endocytosis [202]. In the 
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treatment of CLL, it has been reported that > 80 % of CD20 is removed from 
circulating B cells 1 h after the infusion of CD20 mAb. The loss of CD20 occurs 
through both internalization and trogocytosis [55].  
 
 
1.6.2. Conjugation of EBNA3C to antibodies specific against CD19, CD20, CD21, 
and CD22 
 
Our group has previously demonstrated that lymphoma cells treated with AgAbs 
are able to efficiently present well-characterized single EBV epitopes [168]. 
However, delivered antigen can only be presented if CD4+ T cell epitope and 
patient-specific HLA class II haplotype portray a compatible match. Therefore, 
single-epitope AgAbs will likely require cost-expensive treatment strategies 
using personalized drugs. In our last publication, we have shown that long-
segment AgAbs can efficiently vehicle large antigen attachments into target cells 
followed by successful epitope presentation. Indeed, large fragments of up to 321 
aa of the Epstein-Barr nuclear antigen 3C (EBNA3C), which is an immunogenic 
latent EBV antigen essential for in vitro B cell growth transformation, were 
attached to the C-terminus end of the antibody molecules [168]. Treatment with 
long-segment AgAbs could be adapted to a large number of patients with diverse 
HLA class II haplotypes. The breadth of the immunogenic epitope repertoire 
within the introduced large antigen segment is a critical factor for the immune 
response amplitude as it leads to an enlargement in number and diversity of 
memory T cell clones that can be activated. Owing to the high EBV 
seroprevalence in the adult human population worldwide, most individuals 
possess memory T cells against EBV. Studies have shown that healthy EBV-
seropositive subjects possess high frequency and magnitude of EBV latent 
antigen-specific memory CD4+ T cells in order to control EBV-induced B 
lymphoproliferations [83, 85]. Indeed, CD4+ T cell responses specific to EBNA3C 
are detectable in the majority of healthy EBV carriers [203, 204]. Moreover, 
EBNA3C is a rich source of highly variable CD4+ T cell epitopes and 70 % of  
tested donors were reactive to at least 1 of the 11 priorly determined epitopes 
[85].  In this work, large fragments of EBNA3C were conjugated to the C-
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terminus of anti-CD19, -CD20, -CD21 and -CD22 antibodies in order to elicit a 
strong anti-viral CD4+ CTL response. For the construction of AgAbs, the open 
reading frame (ORF) sequence of EBNA3C was split into three fragments with 
overlapping regions of 60 bp, or 20 aa. A schematic representation of the 
EBNA3C protein fragments (aa 1 – 341, 322 – 672, and 653 – 992) is given in 
Figure 7.  
 
 
 
 
 
 
 
 
Figure 7: Schematic representation of the EBNA3C protein with position and acronyms of 
CD4+ T cell epitopes. The location of the antigen subdomains used for the construction of the 
AgAbs is referred to as EBNA3C-#1 (aa 1 – 341), -#2 (aa 322 – 672) and -#3 (aa 653 – 992). The 
epitopes located at position aa 325 – 339 (ENP) and aa 649 – 660 (PQC) are shared by EBNA3C-
#1 and -#2 and EBNA3C-#2 and -#3, respectively. 
 
A detailed list of the currently identified EBNA3C CD4+ T cell epitopes is 
displayed in Table 3.  
 
Table 3: Identified CD4+ T cell epitopes in the EBNA3C protein as encoded by EBV strain 
B95.8. For the generation of EBNA3C-AgAbs, the sequence was split into three fragments (aa 1 - 
341, aa 322 - 672, and aa 653 - 922) with overlapping regions of 20 aa. *: peptides used in this 
study (modified from [77]). 
EBNA3C 
segment 
Epitope 
coordinates 
Epitope sequence Reference 
Peptide 
acronym 
-#1  
(aa 1 - 341) 
66-80 NRGWMQRIRRRRRR [205] NRG 
100-119 PHDITYPYTARNIRDAACRAV [89] PHD 
141-155 ILCFVMAARQRLQDI [205] ILC 
-#1/ -#2 325-339 ENPYHARRGIKEHVI [168] ENP* 
-#2  
(aa 322 - 672) 
386-400 SDDELPYIDPNMEPV [205] SDD* 
401-415 QQRPVMFVSRVPAKK [205] QQR 
546-560 QKRAAPPTVSPSDTG [205] QKR 
586-600 PPAAGPPAAGPRILA [205] PPA 
626-640 PPVVRMFMRERQLPQ [205] PPV* 
-#2/ -#3 649-660 PQCFWEMRAGREITQ [205] PQC 
-#3  
(aa 653 - 992) 
741-760 PAPQAPYQGYQEPPAPQAPY [206] PAP 
916-930 PSMPFASDYSQGAFT [205] PSM 
961-986 AQEILSDNSEISVFPK [205] AQE* 
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A schematic representation of the Ig heavy chain and light chain genes of the 
generated AgAbs with different EBNA3C segments is displayed in Figure 8a. The 
fully assembled antibody molecule is composed of two light chains and two 
EBNA3C segment containing heavy chains (Figure 8b).  
 
 
 
 
 
 
Figure 8: Schematic representation of EBNA3C-AgAbs. (a) Ig heavy chain and light chain 
genes: EBNA3C segments (EBNA3C-#1, -#2, -#3) are attached to the C-termini of heavy chains, 
respectively. (b) Fully assembled EBNA3C-AgAb molecules composed of two copies of light 
chains and two copies of heavy chains containing EBNA3C segments. Dark grey: human CD-
specific variable region. Light grey: mouse IgG2a constant region. Yellow: EBNA3C-#1. Red: 
EBNA3C-#2. Blue: EBNA3C-#3. 
 
(a) 
(b) 
  INTRODUCTION  
 
 28 
1.7. CLL as an attractive candidate for AgAb treatment 
 
Aggressive chemotherapy is particularly harmful for patients with advanced age, 
who are most of the CLL subjects [207, 208]. Emerging immunotherapy options, 
such as customized CAR T cell therapy, HSCT, and medication with lenalidomide 
or checkpoint inhibitors have illustrated that immune system modification can 
translate into T cell-mediated targeting of CLL cells [64, 209-211]. In this context, 
CLL is a slow-growing tumor, which gives patients time for generating immune 
responses against tumor cells during immunotherapy [212]. 
In this study, AgAbs with large antigen conjugations are proposed to redirect 
EBV-specific CD4+ CTLs onto CLL cells from a large majority of CLL patients. This 
strategy is supported by the following observations: (1) Although CLL is 
characterized by a tumor-induced T cell dysfunction [64, 213-215], it was 
recently found that EBV-specific CD8+ T cells are not functionally impaired in 
terms of cytokine production and cytotoxicity [216]. (2) HLA class II molecules 
are expressed on nearly all CLL cells of the peripheral blood in early stage 
subjects [217]. (3) Most cells in most cases show positive expression patterns for 
CD19 and CD20, although the expression pattern of CD21, and CD22 is more 
variable [218]. (4) CD20-directed antibodies such as rituximab demonstrated 
higher internalization levels and faster processing in CLL compared to FL and 
diffuse large B cell lymphoma (DLBCL), which showed very sparse 
internalization [3, 55, 219]. Thus, first-line treatment with rituximab plus 
chemotherapy was observed to be more beneficial in DLBCL and FL than in CLL 
[20, 220]. The effect has been ascribed to low CD20 expression on CLL cells, 
however, internalization remains a plausible reason [221] since CLL patients 
have often been reported to consume extensive amounts of rituximab and are 
therefore delivered higher doses than patients with FL or DLBCL [20, 220]. 
Contrary, AgAbs will benefit from high receptor internalization rates, which 
results in enhanced antigen uptake of CLL cells. Treating CLL cells with AgAbs 
may therefore be particularly effective in eliminating the malignancy. 
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1.8. Objectives 
 
Previous work from our group has explored the immunotherapeutic potential of 
AgAbs with single epitope conjugations in inducing recognition and killing of 
AgAb-treated Burkitt’s lymphoma cells by HLA-matched CD4+ T cell clones 
derived from healthy donors in vitro. These AgAbs were also shown to stimulate 
memory EBV-specific CD4+ T cells from the peripheral blood of healthy EBV 
carriers. Moreover, AgAbs with large antigen attachments of up to 321 aa 
showed efficient stimulation of a particular CD4+ T cell clone. Thus, large-
segment AgAbs are likely to work for almost every patient independent of its 
HLA class II haplotype, as these compounds can deliver presentable epitopes to 
most of all possible HLA class II types [168].  
Several transgenic mouse models of CLL could be used to test the therapeutic 
efficiency of AgAbs in vivo, however, they show a long latency phase until the 
disease develops [222]. Moreover, they are not susceptible to infection with EBV. 
The therapeutic potential of AgAbs has therefore been evaluated ex vivo by using 
antibodies conjugated with highly immunogenic large EBV antigens against CLL 
blood samples. A more detailed proposal is outlined in the following: 
 
- Cloning of the complete EBV B95.8 EBNA3C ORF fragmented into three 
large segments (bp 1 – 1023, bp 964 – 2016, bp 1957 – 2976) to the C-
terminus of mAb heavy chains (mouse IgG2a) specific to human CD19, 
CD20, CD21, and CD22, respectively. 
- Expressing these AgAbs in human embryonic kidney (HEK293) cells using 
transient transfection, and quality and quantity assessment by Western 
blot and ELISA. 
- Analyzing the efficacy of these AgAbs to specifically deliver peptides for 
HLA class II-restricted presentation on APCs through binding studies and 
T cell activation assays. 
- Testing the potential of AgAbs to induce ex vivo expansion of EBNA3C-
specific CD4+ T cells from healthy donor blood samples treated with all 
twelve EBNA3C-AgAbs (anti-CD19, CD20, CD21, CD22 conjugated with 
EBNA3C-#1, -#2, -#3, respectively). 
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- Recruitment of peripheral blood samples from twelve treatment-naïve 
CLL patients, and analysis of T cell and CLL cell frequencies and the 
expression of CD19, CD20, CD21, CD22, and HLA class II molecules on CLL 
cells through flow cytometry immunophenotyping. 
- Ex vivo expansion EBNA3C-specific CD4+ T cells from CLL patients using 
EBNA3C-AgAbs. 
- Assessment of T cell function and specificity against EBNA3C and 
synthesized EBNA3C CD4+ T cell peptides using IFN-γ ELISA. 
- Evaluating the cytotoxic potential of these T cells in killing primary CLL 
cells or LCLs treated with AgAbs using calcein-AM (CAM) assays, and their 
ability to release GrB and express CD107a upon activation. 
 
The outcome of this ex vivo study will help us to evaluate the potency of AgAbs to 
treat CLL. 
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2. RESULTS 
 
The key experimental findings are described in this chapter including the 
generation and characterization of EBNA3C-AgAbs, the expansion of EBNA3C-
specific CD4+ T cells derived from CLL subjects and the recognition and killing of 
primary CLL cells by these autologous CD4+ T cells through the perforin/GrB-
mediated pathway.  
 
 
2.1. Generation of EBNA3C-AgAbs 
 
EBNA3C-AgAbs were constructed through the conjugation of three EBNA3C 
segments to CD19, CD20, CD21, or CD22-specific antibodies to generate a set of 
twelve AgAbs. The generation of anti-human CD20 antibodies conjugated with 
EBNA3C-#1, -#2, and -#3 is exemplarily demonstrated in this thesis. Similarly, 
DNA sequences of EBNA3C-AgAbs directed against CD19, CD21, and CD22, and 
control isotype EBNA3C-AgAbs (mouse IgG2a anti-mouse CD22 coupled with 
EBNA3C segments) were constructed using PCR-based cloning, enzymatic 
digestion, ligation, plasmid screening, transformation, and recombinant 
production in HEK293 cells. A detailed protocol is given in ǲMaterial and Methodsǳ ȋChapter 4.2.1.). 
 
 
2.1.1. PCR-based cloning of anti-CD20 EBNA3C-AgAbs 
 
The DNA sequences of antibody heavy chain and antigen attachment were 
amplified through PCR-based cloning. For DNA construction of anti-human CD20 
antibodies conjugated with either EBNA3C-#1, -#2, or -#3, the ORF of the 
complete EBNA3C antigen was truncated into three segments and cloned to the 
heavy chain C-terminus of the anti-human CD20 antibody through overlap PCR.  
To this end, the constant heavy chain domains 1 to 3 (CH1 – CH3) of the mouse 
IgG2a anti-human CD20 antibody sequence were amplified from a plasmid 
available to the laboratory (B560). EcoRI restriction endonuclease sites were 
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added upstream of the start codon using oligonucleotide primers. Other primers 
were inserted to eliminate the heavy chain stop codon of the Ig heavy chain at 
the C-terminus and to allow an overlap with the N-terminal sequence of each 
EBNA3C segment. DNA sequences of EBNA3C-#1 (bp 1 – 1023), -#2 (bp 964 – 
2016), and -#3 (bp 1957 – 2976) were amplified from plasmid B338 B_E and 
B338 X_D. Overlapping flanks were introduced upstream of the N-termini, which 
align with the C-terminal sequences of the CH3 mouse IgG2a segment of the anti-
human CD20 antibody. A stop codon (TGA) and a HindIII restriction 
endonuclease site were added at the C-terminus of each EBNA3C segment via the 
insertion of primers. PCR products were loaded on a 1 % agarose gel. In Figure 9, 
PCR 4, 5, and 6 show DNA fragments that encode the anti-CD20 mAb heavy chain 
(CH1 – CH3 mouse IgG2a anti-human CD20) with  flanks at the C-terminus that 
overlap with the N-terminus of gene segment EBNA3C-#1, -#2, and -#3, 
respectively. PCR 13, 14, and 15 display DNA fragments that encode EBNA3C-#1, 
-#2, and -#3 with overlapping flanks at the N-terminus, which match the C-
terminal sequences of the CH3 mouse IgG2a of the anti-CD20 mAb heavy chain, 
respectively. The resulting DNA fragments (Ig heavy chains and antigen 
conjugation sequences) were fused together via overlap PCR to generate the 
genes of interest (GOI). The fused constructs were analyzed on a 1 % agarose gel 
shown in Figure 9. PCR 19, 20, and 21 display DNA fragments that encode CH1 – 
CH3 (mouse IgG2a anti-human CD20) + EBNA3C-#1, -#2, and -#3, respectively. 
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Figure 9: Analysis of PCR products after electrophoresis on a 1 % agarose gel. PCR 4, 5, and 
6 show DNA fragments that encode the anti-CD20 mAb heavy chain (CH1 – CH3 mouse IgG2a anti-
human CD20) with flanks at the C-terminus that overlap with the N-terminus of gene segment 
EBNA3C-#1 (bp 1 – 1023), -#2 (bp 964 – 2016), and -#3 (bp 1957 – 2976), respectively. PCR 13, 
14, and 15 present the DNA fragments that encode EBNA3C-#1, -#2, and -#3 with overlapping 
flanks at the N-terminus to CH3 mouse IgG2a of the anti-CD20 mAb heavy chain. PCR 19, 20, and 
21 show DNA fragments that encode the complete constructs consisting of CH1-CH3 (mouse IgG2a 
anti-human CD20) + EBNA3C-#1, -#2, and -#3, respectively. The expected size of the products is 
shown on each PCR analysis gel. DNA fragments with the correct size (red quadrangle) were cut 
out and extracted from the gel. 
 
 
2.1.2. Ligation of AgAb heavy chain genes into backbone vectors and 
transformation of plasmids into bacteria 
 
Having digested the AgAb heavy chain genes and the pRK5 plasmid backbone 
with EcoRI and HindIII, the compatible constructs were ligated by using T4 DNA 
ligase yielding in plasmids that carry genes for CH1 – CH3 (mouse IgG2a anti-
human CD20) + EBNA3C-#1 (B1205), -#2 (B1206), and -#3 (B1207), 
respectively. Electro-competent DH5 cells were transformed with the plasmids. 
Finally, individual colonies were analyzed and selected for the correct plasmid 
content. The isolated and purified DNA was digested with EcoRI and HindIII 
restriction enzymes for size analysis. In Figure 10, two bands per plasmid were 
detected on the analyses gels, one for the backbone vector (4640 bp) and the 
other one for the GOI (2442 bp, 2496 bp, or 2442 bp for B1205, B1206, or 
B1207, respectively). The final products were sequenced by Eurofins and the 
identity and integrity of the constructs identified. 
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2.1.3 Transfection and recombinant production of anti-CD20 EBNA3C-AgAbs 
 
Anti-CD20 antibodies with and without EBNA3C conjugation were produced in 
HEK293 cells cultured in FreeStyleTM 293 Expression Medium. Transfection of 
the producer cells with plasmids encoding heavy and light chain molecules was 
performed with polyethylenimine (PEI). The expressed fragments were 
assembled into whole antibody molecules and secreted. The expression profile of 
anti-CD20 antibodies with and without EBNA3C conjugation was determined 
using IgG2a ELISA. As Figure 11 shows, anti-CD20 mAb was expressed at 
relatively high levels (approx. 670 ng/mL). Lower expression levels were 
recorded for EBNA3C-conjugated anti-CD20 AgAbs. The degree of expression 
efficiency varied depending on the EBNA3C segment conjugation. The 
attachment of EBNA3C-#1 (approx. 70 ng/mL) or -#3 (approx. 40 ng/mL) led to 
markedly reduced production yields whereas the attachment of EBNA3C-#2 
resulted in minor yield reduction (approx. 580 ng/mL). Thus, it is likely that the 
antigen attachment of EBNA3C-#1 and -#3 led to inhibitory effects in the 
antibody assembly through steric hindrance.  
 
 
 
 
 
 
CD20 native
CD20+EBNA3C-#1
CD20+EBNA3C-#2
CD20+EBNA3C-#3
Figure 11: Transient expression 
profile of anti-human CD20 antibody 
with and without conjugation of 
EBNA3C-#1, -#2, and -#3 in HEK293 
cells after 3 d. Production levels were 
determined by IgG2a ELISA. 
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Figure 10: Digestion analysis of plasmids on a 1 % 
agarose gel. Digested DNA fragments encoding CH1 – CH3 
(mouse IgG2a anti-human CD20) + EBNA3C-#1 (B1205), 
-#2 (B1206), and -#3 (B1207), respectively, are shown. 
The size of the digestion products is given above each 
analysis gel. 
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The panel of EBNA3C-AgAbs directed against CD19, CD21, and CD22 showed 
expression levels similar to the ones observed with EBNA3C-conjugated anti-
CD20 AgAbs (data not shown). The harvested supernatants were filtered 
through a 0.22 µm pore size syringe filter and 100 mL were concentrated to 1 
mL through a molecular weight cut-off (MWCO) of 10,000 Da (Vivaspin® 20) by 
ultrafiltration. The molecular weights of the assembled anti-CD20 antibodies 
with and without EBNA3C conjugation were evaluated through Western blotting 
(Figure 12a). Additionally, the cell extracts of transfected 293 cells were 
analyzed under reduced conditions using -mercaptoethanol (Figure 12b). 
 
Figure 12: Expression profile of anti-human CD20 
antibodies with and without attached EBNA3C 
segments analyzed by Western blot. (a) 
Supernatants of transfected 293 cultures were 
analyzed under native conditions. The SDS-PAGE was 
run on a 7.5 % separating gel with 2 ng of antibody 
loaded per lane. The chemiluminescent Western blot 
was exposed to an x-ray film for 5 min. Protein bands 
of the complete antibody and other variations of the Ig 
heavy and light chain complexes were detected. The 
expected molecular weights are given in the graph. (b) 
Transfected 293 cell extracts were analyzed under 
reduced conditions using -mercaptoethanol. Ig heavy 
and light chain bands of the antibody and variations of 
the heavy chain were detected. The SDS-PAGE was run 
on a 12.5 % separating gel with 18 ɊL of each 293 cell 
extract loaded per lane. The chemiluminescent 
Western blot was exposed to an x-ray film for 5 min. 
The expected molecular weights of Ig heavy chains are 
given in the graph. Ig light chains are expressed at 26 kDa. For the visualization of the antibody 
proteins, a detection antibody specific to mouse Ig heavy and light chain was used. kDa: 
kilodalton. 
 
As expected, assembled EBNA3C-conjugated anti-CD20 AgAbs delivered signals 
of higher molecular weights than the control native antibody. Some degree of 
antibody fragmentation occurred in antibodies both with and without EBNA3C-
conjugation. Degradation of anti-CD20 EBNA3C-AgAbs to the molecular weight 
of the native antibody (most prominent band at approximately 150-160 kDa) 
was observed in all analyzed samples. Under reduced conditions, EBNA3C-
conjugated heavy chains showed distinctly higher molecular weights than the 
(b) (a
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control native molecules. Comparably to fully assembled AgAbs, however, 
molecular weight variations of these conjugated heavy chain molecules were 
detected here as well. 
 
 
2.2. EBNA3C-AgAbs are functional and induce potent immune responses in 
healthy donors 
 
EBNA3C-AgAbs were tested on their ability to bind target receptors on APCs and 
to present their antigen moiety to a specific CD4+ T cell clone. Moreover, 
EBNA3C-specific CD4+ CTLs were expanded from a healthy individual through 
the repetitive stimulation with EBNA3C-AgAbs.  
 
 
2.2.1. Efficient target receptor binding by EBNA3C-AgAbs 
 
Target receptor binding efficacy of anti-CD20+EBNA3C-#1, -#2, and -#3 AgAbs 
was evaluated and compared to the control native antibody by flow cytometry 
analysis. Indeed, primary B cells were recognized by EBNA3C-AgAbs with the 
same efficiency as the control native antibody. Non-specific binding of EBNA3C-
AgAbs to endogenous Fc receptors (FcRs) through the antibody Fc domain 
(murine IgG2a) or through non-specific ionic and hydrophobic interactions was 
investigated using a commercial control isotype mouse IgG2a antibody, and a 
control isotype IgG2a anti-mouse CD22 antibody conjugated with EBNA3C-#2. 
Both tested antibodies showed no binding to the target cells, which excludes 
non-specific binding of AgAbs. The fluorescent signal of all tested cell samples 
(grey) is compared to the signal of cells stained with the secondary antibody only 
(white). The results are presented in Figure 13. 
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Figure 13: Binding characteristics of EBNA3C-conjugated anti-human CD20 AgAbs. Primary 
B cells derived from a healthy volunteer were incubated with anti-CD20 antibodies without and 
with EBNA3C conjugation (a), with a commercial control isotype mouse IgG2a antibody (b), or 
with a control isotype mouse Ig2a anti-mouse CD22 antibody conjugated with EBNA3C-#2 (c). 
Target cell binding was assessed by flow cytometry after incubation with a secondary anti-mouse 
IgG2a PE antibody. 
 
2.2.2. EBNA3C-AgAbs vehicle large antigen conjugations into target cells that 
subsequently present HLA-compatible epitopes  
 
The ability of EBNA3C-AgAb-treated target cells to present their antigen moiety 
to specific CD4+ T cell clones was tested by performing T cell activation assays 
with IFN-γ release as surrogate marker. To this end, EBNA3C ENP-specific CD4+ 
T cells derived from a healthy subject (H1) were co-cultured with EBV-
transformed autologous B cells, named LCLs, that were used as APCs. These 
target cells were incubated with anti-CD22 EBNA3C-#1, -#2, -#3, control native 
antibody, control ENP peptide, or mock medium at an effector to target (E:T) 
ratio of 2:1. ENP-specific CD4+ T cells were exclusively activated by LCLs that 
were treated with anti-CD22 directed antibodies fused to EBNA3C-#1 (aa 1 - 
341) or -#2 (aa 322 - 672) antigen segments of which both include the ENP 
epitope. Especially the application of EBNA3C-#2 AgAbs induced strong T cell 
signals with much higher levels than mediated by the ENP peptide. Interestingly, 
these constructs induced a far better T cell response than the EBNA3C-#1-
conjugated molecules. As expected, LCLs treated with mock medium, the control 
(a)                                                        
IgG2a 
anti-human CD20       anti-human CD20         anti-human CD20                   anti-human CD20 
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native anti-CD22 antibody, or the anti-CD22+EBNA3C-#3 AgAb that does not 
contain the ENP epitope, did not induce any detectable IFN-γ signal (Figure 14a). 
These results show that EBNA3C-AgAbs efficiently vehicle large EBNA3C 
segments into target B cells with subsequent epitope recognition by EBV-specific 
T cell clones. The same assay was carried out using CD19- or CD21-specific 
AgAbs, which had a very similar outcome (Figure 14b). In a next step, polyclonal 
EBNA3C-specific CD4+ T cells were ex vivo expanded from another healthy 
individual (H2) by repetitive stimulation with PBMCs loaded with EBNA3C-
AgAbs. At passage 6, this T cell line showed upregulation of CD69, an early T cell 
activation marker, upon stimulation with EBNA3C-AgAb-treated LCLs (Figure 
14c). Strong IFN-γ release was recorded after exposure of these T cells to target 
LCLs pulsed with EBNA3C-#2 AgAbs. Exposure to the other two AgAbs (-#1 and -
#3), the control isotype EBNA3C-#2 AgAb, or the unconjugated antibody did not 
result in any T cell response (Figure 14d). The same T cell batch showed potent 
cytotoxicity against autologous LCLs pulsed with EBN3C-#2 AgAbs. The cytotoxic 
response was inhibited by pre-treatment of the T cells with concanamycin A 
(CMA), a vacuolar type H+-ATPase (V-ATPase) inhibitor (Figure 14e). These 
results demonstrate the ability of EBNA3C-AgAbs to induce expansion of fully 
functional EBNA3C-specific CD4+ CTLs from healthy individuals. 
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Figure 14: Target B cells loaded with EBNA3C-AgAbs stimulate the proliferation, activation 
and cytotoxicity of EBV-specific CD4+ T cells. (a) EBNA3C ENP-specific CD4+ T cell clones 
derived from a healthy subject (H1) recognize autologous LCLs that were pulsed with anti-CD22-
EBNA3C#1- or anti-CD22-EBNA3C#2 AgAbs. Both of these antigen conjugations comprise the 
 CD3                                                    CD4                                                          CD4 
(c) H2: EBNA3C CD4+ T cell line 
      CD69 T cell activation through co-culture with EBNA3C-AgAb-pulsed autologous LCLs  
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ENP epitope and induce a strong T cell IFN- response as the control ENP peptide does. In 
contrast, untreated LCLs, and LCLs pulsed with the control native anti-CD22 antibody, or with the 
anti-CD22+EBNA3C#3 AgAb (that does not contain ENP) did not show any detectable IFN- 
signal. The IFN- release assay was performed at E:T = 2:1. (b) Same setup as in (a) but with 
EBNA3C-AgAbs specific to CD19 or CD21. (c-e) EBNA3C-AgAbs stimulate the proliferation of 
EBV-specific CD4+ CTLs from a healthy individual (H2). (c) PBMCs from H2 were repeatedly 
stimulated with all twelve EBNA3C-AgAbs. A flow cytometry staining with CD3- and CD4-specific 
antibodies after 6 rounds of stimulation with AgAbs showed that the outgrowing T cells were 
mainly CD3+ CD4+ (left and middle panel). The expanded T cells were co-cultured with 
autologous LCLs treated with anti-CD22-EBNA3C-AgAbs and stained for CD69, which is 
upregulated on activated CD3+ CD4+ T cells (right panel). (d) The IFN- release assay was 
performed with T cells tested in (c) under conditions described in (a). T cell response to 
autologous LCLs pulsed with EBNA3C-#2-conjugated anti-CD22 antibodies was recorded. In 
contrast, untreated LCLs, and LCLs pulsed with the control native anti-CD22 antibody, or with 
EBNA3C-#1 or -#3 AgAb did not show any detectable IFN- signal. (e) This figure shows the 
results of a cytotoxicity assay performed with autologous LCLs pulsed with anti-CD22 EBNA3C-
AgAbs for 16 h in the presence or absence of CMA. As negative controls, non-conjugated 
antibodies, EBNA3C-#1- and -#3-AgAbs, or mock medium only were applied. Target cells were 
stained with CAM. Autologous EBNA3C-specific CD4+ T cells were added at increasing E:T ratios 
(1:1; 3:1; 10:1; 30:1) for 3 h. All assays were performed in triplicates with means and standard 
deviations displayed in the graphs. 
 
 
2.3. AgAb treatment in CLL ex vivo  
 
2.3.1. Clinical characteristics of CLL patients 
 
Peripheral blood samples (50 mL) of twelve treatment-naïve CLL patients (seven 
male and five female) were collected in this ex vivo study. Informed consent was 
collected before the blood donation. All subjects fulfilled immunophenotypical 
criteria of CLL. The interval between diagnosis with CLL and study inclusion 
varied from 51 to 323 months (mean = 104 months). The white blood cell (WBC) 
count of the recruited patients ranged from 22 to 228 x 109/L with a mean value 
of 67 x 109/L at the time of study inclusion. The CD3+ T cell population (2.4 to 
20.8 %) consisted of 1.0 to 10.0 % of CD4+ T cells and 0.5 to 15.0 %, CD8+ T cells, 
with a CD4/CD8 ratio that was below the normal value of two in half of the 
patients (P3, P4, P5, P6, P10, P12). An extremely low CD4/CD8 ratio of 0.1 was 
recorded in subject P6. CLL cells were detected at a frequency of 73.3 to 94.2 % 
with high expression levels of HLA-DP, -DQ, and -DR between 99.8 to 100.0 %. In 
contrast, normal B cells (CD19+ CD5-) were measured at very low concentrations 
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between 0.1 and 3.6 %. B cells (normal and malignant) isolated with CD19-
specific antibodies were positive for CD20 (90.0 to 99.8 %), CD21 (74.0 to 99.7 
%), and CD22 (54.8 to 99.7 %). The participating clinical side performed 
chromosome analysis of nine CLL cell subjects using fluorescence in situ 
hybridization (FISH). 13q- (P2, P4, P9, P11, P12) followed by 14q- (P3, P7) were 
the most frequent abnormalities identified.  The chromosome profile of two 
subjects was normal (P1, P8). The IGHV mutational status was only determined 
in two patients (P4, P10), where it was found mutated. An overview of all CLL 
patients is given in Table 4. 
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            Table 4: Demographic, clinical and biological characteristics of treatment-naïve CLL patients. m: male. f: female. WBC: white blood cell. n/d: not      
            determined. mt: mutated. del: deletion. 
 
 
CLL 
subject 
Sex Age 
Between 
diagnosis 
to study 
inclusion 
(months) 
WBC 
count 
(109/L) 
IGHV FISH 
CLL cells CD19+ cells T cells 
CD19+ 
CD5+ (% 
of PBMC) 
HLA class II+ 
(% of  CD19+ 
CD5+) 
CD20 CD21 CD22 
CD3+ T-
cells (% of 
PBMC) 
Ratio 
CD4/CD8  
T-cells 
P1 f 68 63 22 n/d normal 80.7 99.9 95.5 99.0 54.8 9.6 2.3 
P2 f 73 55 49 n/d del 13q14, trisomy 12q13 73.5 99.9 99.7 99.7 86.5 20.8 2.4 
P3 f 76 73 227 n/d del 14q32 92.3 100.0 98.4 93.5 96.9 3.3 0.8 
P4 f 58 96 61 mt del 13q14 91.2 99.9 99.4 74.0 93.4 3.9 0.9 
P5 f 75 323 45 n/d n/d 73.3 99.8 98.5 91.4 96.8 20.8 0.8 
P6 m 77 75 38 n/d n/d 81.7 99.8 98.4 94.4 97.6 16.6 0.1 
P7 m 74 82 38 n/d del 14q32 86.8 100.0 99.8 98.1 98.6 11.5 5.0 
P8 m 68 123 66 n/d normal 73.7 99.9 97.1 93.7 99.7 2.4 2.3 
P9 m 68 165 35 n/d 
del 13q14, nullisomy 13q14, 
del of distal IgH gene locus 
94.2 100.0 99.0 98.3 99.2 3.5 4.3 
P10 m 65 85 107 mt n/d 91.6 99.8 98.2 92.2 97.4 3.8 1.4 
P11 m 63 51 25 n/d del 13q14 88.1 99.8 89.8 95.1 87.7 10.3 2.6 
P12 m 70 54 88 n/d del 13q14; trisomy 14q32 92.5 99.8 97.9 97.5 57.4 2.5 1.1 
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2.3.2. AgAbs stimulate the expansion of T cells from CLL patients 
 
EBNA3C-specific CD4+ T cells were expanded ex vivo through repetitive biweekly 
stimulation with autologous APCs (PBMCs or LCLs) treated with all twelve 
EBNA3C-AgAbs (anti-CD19, -CD20, -CD21, -CD22 antibodies conjugated with 
EBNA3C-#1, -#2, and -#3, respectively). CD4+ T cell enrichment was measured 
over the course of several stimulation rounds by flow cytometry analyses using 
CD3 FITC and CD4 PE-Cy5 antibodies for cell surface receptor staining (Figure 
15a). The outgrowth of CD4+ T cells representative for four CLL subjects (P7, P2, 
P1, P6) is shown in Figure 15b. The expansion of CD4+ T cells, however, was 
accompanied by the outgrowth of CD8+ T cells in nine patient samples (P1, P6 
shown in Figure 15b, and P3, P4, P5, P8, P9, P10, P11 not shown). Generally, the 
proportions of CD4+ T cells progressively increased with the number of 
stimulation cycles. In some cases (P1, P6 shown in Figure 15b), however, CD8+ T 
cells were depleted after 8 stimulation rounds by using CD8a PE antibodies and 
anti-PE-directed MACS beads. The enriched CD4+ T cells populations remained 
pure during the next two stimulation cycles. In addition, normal B cells from 
each patient were transformed with EBV to obtain LCLs that can be used as 
APCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 RESULTS  
 
 44 
(a)            P7 
 
 
 
 
 
 
 
 
 
 
 
(b)       
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: EBNA3C-AgAbs stimulate the ex vivo outgrowth of CD4+ T cells from CLL 
patients. (a) Expansion of CD4+ T cells was monitored by flow cytometry. PBMCs from CLL 
subject P7 were repetitively challenged with all twelve EBNA3C-AgAbs (anti-CD19, -CD21, -CD20, 
-CD22 antibodies conjugated with EBNA3C-#1, -#2, and -#3, respectively) every two weeks. 
Double positive CD3+ CD4+ T cells are located in the upper right quadrant with their percentage 
indicated. (b) Summary of ex vivo expansion data of T cell populations from four patients (P7, P2, 
P1, P6) over time, as defined by flow cytometry. In P1 and P6, CD8+ T cell subsets were depleted 
at stimulation cycle 8 (week 16) using MACS beads. w: week. 
 
 
2.3.3. Patient-derived CD4+ T cells are specific for EBNA3C 
 
IFN-γ release and CAM cytotoxicity assays were performed with CD4+ T cell lines 
ex vivo expanded from CLL patient blood samples by stimulation with EBNA3C-
AgAbs. These T cells were co-cultured with autologous LCLs that were pulsed 
with EBNA3C-AgAbs in order to find out their specificity and cytotoxic potential. 
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2.3.3.1. EBNA3C-specific CD4+ T cells specifically recognize LCLs treated with 
AgAbs 
 
Antigen specificity of the CD4+ T cell lines expanded from CLL patient blood was 
assessed by using autologous AgAb-treated LCLs as APCs. Therefore, LCLs were 
individually loaded with 50 ng, 10 ng, or 1 ng of anti-CD20-directed EBNA3C-#1, 
-#2, or-#3 AgAbs, the control native mAb, or incubated in medium only, and co-
cultured with autologous CD4+ T cells at E:T = 5:1. The release of IFN- into the 
supernatant was measured by ELISA. A panel of assay results is presented in 
Figure 16 showing that CD4+ T cell lines derived from P9, P1, and P8 possess 
specificity to EBNA3C-#1, -#2, or -#3, respectively, with varying levels in their 
IFN-γ response. A set of four HLA class II-restricted EBNA3C peptides was 
synthesized to confirm the specificity of the EBNA3C-specific T cell responses 
(see Table 3). EBNA3C-#2-specific CD4+ T cells of P1 recognized target cells 
pulsed with the PPV peptide, which is located in segment EBNA3C-#2. EBNA3C-
#3-specific CD4+ T cells of P8 were reactive against the AQE peptide. This HLA 
class II-restricted epitope is located in EBNA3C-#3.  
 
 
 
 
 
 
 
Figure 16: CD4+ T cells ex vivo expanded through EBNA3C-AgAb stimulation recognize 
autologous LCLs treated with EBNA3C-AgAbs. IFN-γ release assays were performed with LCLs 
pulsed with increasing amounts of EBNA3C-AgAbs or HLA class II-restricted EBNA3C peptides. 
As controls, non-conjugated antibodies and unloaded cells were applied. T cell assays were 
performed with ex vivo expanded CD4+ T cells co-cultured with LCLs that were loaded with 
EBNA3C-AgAbs in subject P9 (a), or loaded with EBNA3C-AgAbs or with PPV peptide in subject 
P1 (b), or loaded with EBNA3C-AgAbs or with AQE peptide in subject P8 (c). The IFN- release 
assay was performed at E:T = 5:1. Released IFN- was measured by ELISA. Assays were 
performed in triplicates with means and standard deviations displayed in the bar charts. 
 
IFN-γ responses of all patient-derived CD4+ T cell lines to EBNA3C segments and 
to HLA class II-restricted EBNA3C peptides are summarized in Figure 17a. 
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Notably, specificity to EBNA3C peptides could not be determined in all expanded 
T cell lines since only four out of numerous HLA class II-restricted peptides were 
synthesized and tested. Thus, EBNA3C peptide-specific responses were detected 
for three (PPV, SDD, AQE) of these peptides in six patients. A specific response to 
EBNA3C was observed in all CD4+ T cell lines expanded with EBNA3C-AgAbs. In 
some patients, multiple T cell lines with different EBNA3C segment specificities 
were expanded. Taken all twelve CLL subjects together, T cell specificity could be 
identified for EBNA3C-#1 in three patients (25 %), for EBNA3C-#2 in eight 
patients (67 %), and for EBNA3C-#3 in ten patients (83 %). In seven subjects (58 
%), the expanded T cells had specificity to two EBNA3C segments. In one subject 
(P11), T cell specificities against all three segments were identified (8 %). The 
distribution of EBNA3C- #1-, -#2-, and -#3-specific CD4+ T cell lines expanded 
from all CLL patient blood samples is summarized in Figure 17b.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: EBNA3C specificity of patient-derived CD4+ T cell lines ex vivo expanded 
through the stimulation with AgAbs. The specificities were determined by IFN- release 
assays, in which autologous LCLs were pulsed with EBNA3C-AgAbs or HLA class II-restricted 
EBNA3C peptides, and co-cultured with autologous EBNA3C-specific CD4+ T cells (E:T = 5:1). (a) 
The table indicates the specificity of CD4+ T cells from each patient against EBNA3C (segment or 
peptide). (b) Distribution of EBNA3C-#1, -#2, and -#3-specific CD4+ T cell lines expanded from all 
CLL subjects summarized in a circle diagram: EBNA3C-#1: 25 % (yellow); EBNA3C-#2: 67 % 
(red); EBNA3C-#3: 83 % (blue); EBNA3C-#1, and -#2: 8 % (orange); EBNA3C-#1, and -#3: 8 % 
(green); EBNA3C-#2, and -#3: 42 % (purple); EBNA3C-1, -#2, and -#3: 8 % (center). n/d: not 
determined. 
 
CLL 
subject 
CD4+ T cell 
specificity 
(EBNA3C) 
Epitope 
specificity 
P1 -#2 -#3 PPV 
P2 -#2 -#3 n/d 
P3 -#2 -#3 AQE 
P4 -#2 -#3 AQE 
P5 -#1 -#2 PPV, SDD 
P6 -#3 n/d 
P7 -#3 n/d 
P8 -#2 -#3 AQE 
P9 -#1 -#3 n/d 
P10 -#3 n/d 
P11 -#1 -#2 -#3 n/d 
P12 -#2 SDD 
(a)             (b) 
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2.3.3.2. EBNA3C-specific CD4+ T cells specifically kill LCLs treated with AgAbs 
 
EBNA3C-specific CD4+ T cells expanded from CLL patient blood samples are 
specifically activated by autologous EBNA3C-AgAb-pulsed LCLs as described in 
the previous chapter. Here, these T cell lines are demonstrated to possess 
cytotoxic activity against autologous LCLs treated with EBNA3C-AgAbs.  
The cytotoxic potential of CD4+ T cells was assessed by their ability to directly 
lyse target cells in CAM assays. LCLs were treated with anti-CD20 antibodies 
with or without EBNA3C segment attachments, or incubated in mock medium. 
Thereafter, target cells were loaded with CAM and co-cultured with autologous 
EBNA3C-specific CD4+ T cell lines at increasing E:T ratios from 1:1 to 30:1 for 3 
h. The results shown in Figure 18 exemplarily emphasize the cytotoxic potential 
of three patient-individual CD4+ T cell lines specific to different segments of 
EBNA3C with P1 specific to EBNA3C-#2 (a), P7 specific to EBNA3C-#3 (b), and 
P6 specific to EBNA3C-#3 (c). Thus, LCLs loaded with the immunogenic EBNA3C-
AgAb were specifically killed by the autologous T cell line in an E:T ratio-
dependent manner.  
 
 
 
 
 
 
Figure 18: EBNA3C-specific CD4+ T cells derived from CLL patients kill autologous LCLs 
upon exposure to EBNA3C-AgAbs. In cytotoxicity assays using CAM, 5 x 104 LCLs were pulsed 
with 50 ng of EBNA3C-AgAbs for 16 h. As negative controls, non-conjugated antibodies or mock 
medium was applied. LCLs were then stained with CAM ȋͷ ɊMȌ and autologous EBNA͵C-specific 
CD4+ T cells were added at increasing E:T ratios (1:1; 3:1; 10:1; 30:1). Released calcein was 
quantified by spectrophotometry and the degree of lysis determined. Assays were performed in 
triplicates with means and standard deviations displayed in line graphs. (a-c) The line graphs 
show the results of killing assays performed with cell material from subject P1 (a), P7 (b), and P6 
(c). 
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2.3.3.3. CD8+ T cells co-expanded with EBNA3C-specific CD4+ T cells do not 
recognize or kill EBNA3C-AgAb-treated target cells 
 
The repeated stimulation with EBNA3C-AgAbs led to co-expansion of CD4+ and 
CD8+ T cells in some CLL patient samples. To find out whether the CD8+ T cell 
subsets also possess EBNA3C specificity, T cells were separated into CD4+ and 
CD8+ T cell fractions and individually tested in T cell activation (IFN-γ) and 
cytotoxicity (CAM) assays. In the assays presented in Figure 19, separated CD4+ 
and CD8+ T cell subsets of P1 were co-cultured with autologous EBNA3C-AgAb-
pulsed PBMCs as target cells, which mostly consist of CLL cells. Apart from that, 
both experiments were carried out as previously described. Therefore, CD8+ T 
cells did not show any response to EBNA3C since neither specific recognition 
(Figure 19a) nor direct lysis (Figure 19b) was measured against target cells 
pulsed with EBNA3C-AgAbs. Vice versa, it could clearly be demonstrated that the 
CD4+ subset specifically released IFN- (Figure 19a) and directly killed target 
cells pulsed with EBNA3C-#2 AgAbs (Figure 19b). The same phenomenon was 
observed with co-expanded CD8+ T cell subsets from other CLL patient samples 
(data not shown). It can be concluded that the EBNA3C-specific response is 
exclusively restricted to the CD4+ T cell subset. 
 
 
 
 
 
 
 
 
 
 
Figure 19: Patient-derived CD8+ T cells expanded through stimulation with AgAbs are not 
EBNA3C-specific. Isolated CD4+ and CD8+ T cell subsets were individually assessed on EBNA3C 
specificity in IFN-γ and calcein release assays. (a) Autologous PBMCs were treated with 50 ng of 
EBN3C-#1, -#2, or -#3 AgAbs, non-conjugated antibodies, or mock medium for 8 h. IFN- 
released into the medium was measured by ELISA after co-culture with autologous CD4+ or CD8+ 
T cells. (b) PBMCs were treated as in (a), stained with CAM ȋͷ ɊMȌ, and used in a 3 h CAM assay 
at E:T ratio = 30:1. Both assays were performed in triplicates with means and standard 
deviations shown. 
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2.3.4. EBNA3C-specific CD4+ T cells specifically recognize primary CLL cells 
treated with AgAbs 
 
Previously in this work, ex vivo expanded CD4+ T cells from CLL patients were 
demonstrated to be specific against EBNA3C and possess cytotoxic properties. 
These T cells were then assessed on their ability to recognize AgAb-treated 
primary CLL cells. Therefore, CD5-positive CLL cells from patient P11 were 
purified and used as APCs that were loaded with AgAbs. As in previous IFN-γ 
release assays, CD4+ T cells were added at E:T = 5:1. The CD4+ T cell line used in 
this experiment was previously determined to be specific for EBNA3C-#2 and -
#3 and showed high level IFN-γ secretion against CLL cells that were pulsed with 
either EBNA3C-#2 (5585 + 88 pg/mL at 50 ng) or -#3 (5237 + 681 pg/mL at 50 
ng) AgAbs. As shown in Table 4, CLL patient-derived PBMCs mainly consist of 
CLL cells. Therefore, total PBMCs from which CLL cells were isolated, were also 
directly used in this experiment. The number of PBMCs was set to 5 x 104 CLL 
cells. Both target cell samples induced a T cell response with similar levels of 
IFN-γ release (Figure 20a). As a consequence, further analyses in this 
experimental panel were limited to CLL cells applied through total PBMC pools. T 
cell recognition assays related to the three CLL subjects P5, P1, and P7 restricted 
to EBNA3C-#1, -#2, and -#3, respectively, are shown in Figure 20b-d. These T 
cell lines showed varying levels in their IFN-γ response. CDͶ+ T cells of subject 
P5 secreted high levels of IFN-γ ȋʹͶͷͷ + 198 pg/mL at 50 ng) when co-cultured 
with autologous PBMCs pulsed with EBNA3C-#1 AgAbs. Medium levels of IFN-γ 
(1354 + 90 pg/mL at 50 ng) were secreted by CD4+ T cells of subject P1 that 
were co-cultured with PBMCs treated with EBNA3C-#2 AgAbs. PBMCs of P7 
incubated with EBNA3C-#3-AgAbs only induced a relatively weak IFN-γ release 
(73 + 20 pg/mL at 50 ng) by CD4+ T cells. A correlation between AgAb dose and 
IFN-γ signal was observed in all cases. Target cells cultured with mock medium, 
or control native antibody did not show any specific T cell-induced IFN- release. 
Likewise, target cells pulsed with non-immunogenic EBNA3C-AgAbs (e.g. 
EBN3C-#1, and-#3-AgAbs for the used T cell line of subject P1) did not induce 
any specific T cell response. EBNA3C-specific T cell responses against primary 
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CLL cells could be detected in all twelve patient samples. The intensity of IFN-γ 
release for all patient samples is summarized in Table 5. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 20: Primary CLL cells treated with AgAbs are recognized by autologous EBNA3C-
specific CD4+ cells. T cell activation was determined by the release of IFN-γ as a surrogate 
marker. Primary target cells from four different CLL subjects (5 x 104 CLL cells per test) were 
pulsed with increasing amounts of anti-CD20 antibodies with conjugation of EBNA3C-#1, -#2, or 
-#3. As negative controls, non-conjugated antibodies and mock medium were applied. After co-
culture with effector T cells, IFN- released into the medium was measured by ELISA. The assays 
were performed in triplicates with means and standard deviations displayed in the graphs. (a) 
IFN- assay was performed with CD5-purified CLL cells or total PBMCs from CLL patient P11 
used as APCs. (b-d) IFN- assays were performed with total PBMCs from three other CLL patients 
(P5, P1, P7) used as APCs. 
 
 
2.3.5. EBNA3C-specific CD4+ T cells specifically kill primary CLL cells treated 
with AgAbs 
 
EBNA3C-specific CD4+ T cells expanded from CLL patient blood samples were 
demonstrated to specifically recognize autologous primary CLL cells pulsed with 
EBNA3C-AgAbs. CD4+ T cell-mediated cytotoxicity against primary CLL cells was 
then evaluated through direct target cell lysis assays using CAM, and indirectly 
through measuring upregulated CD107a expression and GrB secretion. The 
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involvement of perforin/GrB in the CTL activity was tested by applying CMA on 
effector T cells.  
 
 
2.3.5.1. Direct target cell killing (calcein release assay) 
 
The ability of patient-derived EBNA3C-specific CD4+ T cells to kill autologous 
LCLs treated with EBNA3C-AgAbs was previously presented in Figure 18. In 
order to demonstrate that these T cells directly kill primary target cells, CAM 
assays were performed using CLL cells as APCs. Briefly, 5 x 104 CLL cells were 
treated with 50 ng of antibodies with or without EBNA3C attachments, or 
incubated in mock medium for 16 h. Thereafter, target cells were loaded with 
CAM and co-cultured with autologous EBNA3C-specific CD4+ T cells at increasing 
E:T ratios from 1:1 to 30:1 for 3 h. CLL cells of P11 (either isolated or in PBMC 
pool) were efficiently killed by autologous CD4+ T cells when these target cell 
samples were pre-treated with EBNA3C-#2- and -#3-AgAbs. Non-specific 
bystander killing was similarly observed against CLL cells purified or in PBMC 
pool. This effect is most likely mediated by non-specific cross-reactivity of 
cytokines released by CD4+ T cells. Since both target cell samples induced CTL 
activity with similar net levels of target cell killing, PBMCs (adjusted to 5 x 104 
CLL cells per sample) were used as target cells for further analyses as presented 
in Figure 21b-e. Thus, CLL cells loaded with AgAbs were specifically killed by the 
autologous T cell lines in an E:T ratio-dependent manner. EBNA3C-#1-specific 
CD4+ T cells of P5 showed high levels of target cell killing that reached a plateau 
of 80 + 1 % at E:T = 10:1 (Figure 21b). P1 EBNA3C-#2-specific CD4+ T cells 
directly lysed target cells pulsed with EBNA3C-#2 AgAb at 52 + 7 % with E:T = 
30:1. However, bystander cytotoxicity was recorded against target cells 
incubated in mock medium, or pulsed with the native control antibody, or with 
EBNA3C-#1-, or -#3-conjugated AgAbs (Figure 21c). Remarkably, P7 EBNA3C-
#3-specific CD4+ T cells, which only gave weak IFN- responses in T cell 
activation assays (see Figure 20d), showed highly efficient target cell killing with 
up to 52 + 2 % at E:T = 30:1 (Figure 21d). Beyond, EBNA3C-specific CD4+ T cell 
lines of all CLL subjects displayed cytotoxic responses against primary CLL cells 
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after EBNA3C-AgAb stimulation irrespectively of the intensity of IFN-γ secretion 
that was recorded in T cell activation assays (summarized in Table 5). Perforin 
secretion blockade through CMA inhibited direct killing of target cells pulsed 
with the immunogenic EBNA3C-AgAb (Figure 21a-d). These results indicate the 
essential role of the perforin-based cytotoxic responses triggered by EBNA3C-
specific CD4+ T cells against CLL cells treated with AgAbs. It can be concluded 
that the large majority of CLL cells treated with AgAbs induces a potent cytotoxic 
T cell response with activation of the perforin/GrB-mediated pathway. In 
addition, killing kinetics induced by EBNA3C-AgAbs with different receptor 
specificities were recorded. Thereby, primary target cells treated with AgAbs 
(here: EBNA3C-#2 AgAbs) against CD19, CD20, CD21, or CD22 were killed by 
effector T cells with similar efficiency (Figure 21e). A repeated-measure Analysis 
of Variance (ANOVA) with the within subject factor ǲE:T ratioǳ ȋͳ:ͳ vs. ͵:ͳ vs. ͳͲ:ͳ vs. ͵Ͳ:ͳȌ and the between subject factor ǲtreatmentǳ ȋunloaded vs. anti-
CD19+EBNA3C-#2 vs. anti-CD20+EBNA3C-#2 vs. anti-CD21+EBNA3C-#2 vs. 
anti-CD22+EBNA3C-#2) was conducted. Two-sided t-tests were used for post-
hoc analyses. The analysis of this experiment yielded a significant main effect of 
the ǲE:T ratioǳ, F(3, 30) = 763.30, p < .001, and of the ǲtreatmentǳ with AgAbs, 
F(4, 10) = 38.31, p < .001. In addition, there was a significant two-way 
interaction between ǲE:T ratioǳ and ǲtreatmentǳ, F(12, 30) = 23.78, p < .001. To 
further explore this interaction, post-hoc t-tests revealed that ǲtreatmentǳ 
unloaded led to significantly lower killing values compared to ǲtreatmentǳ with 
anti-CD19+EBNA3C-#2 only at E:T ratios 3:1, t(4) = 5.27, p = .006, 10:1, t(4) = 
9.80, p = .001, and 30:1, t(4) = 17.49, p > .001. Similarly, ǲtreatmentǳ unloaded 
resulted in significantly lower killing values compared to ǲtreatmentǳ with anti-
CD20+EBNA3C-#2 at E:T ratios 1:1, t(4) = 5.00, p = .007, 3:1, t(4) = 4.99, p = .008, 
10:1, t(4) = 11.63, p > .001, and 30:1, t(4) = 20.19, p > .001. Further, ǲtreatmentǳ 
unloaded led to significantly lower killing values compared to ǲtreatmentǳ with 
anti-CD21+EBNA3C-#2 only at E:T ratios 3:1, t(4) = 3.04, p = .038, 10:1, t(4) = 
6.52, p = .003, and 30:1, t(4) = 8.91, p = .001. And ǲtreatmentǳ unloaded led to 
significantly lower killing values compared to ǲtreatmentǳ with anti-
CD22+EBNA3C-#2 at E:T ratios 1:1, t(4) = 6.05, p = .004, 3:1, t(4) = 3.67, p = .021, 
10:1, t(4) = 7.82, p = .001, and 30:1, t(4) = 9.22, p = .001. It was revealed that 
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AgAbs directed against CD20 compared to CD21 led to significantly lower killing 
values only at E:T ratio 10:1, t(4) = 3.96, p = .017. No other post-hoc t-tests 
reached significance (all ps > .05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Patient-derived EBNA3C-specific CD4+ T cells efficiently kill primary CLL cells 
treated with EBNA3C-AgAbs through perforin/GrB-mediated cytotoxicity. Direct killing of 
primary CLL cells from five patients is shown by using CAM cytotoxicity assays. 5 x 104 target 
cells (CLL cells pure or in PBMC pool) were treated with 50 ng of EBNA3C-AgAbs for 16 h in the 
presence or absence of CMA. As negative controls, non-conjugated antibodies or mock medium 
was applied. Target cells were stained with CAM ȋͷ ɊMȌ and autologous EBNA͵C-specific CD4+ T 
cells were added at increasing E:T ratios (1:1; 3:1; 10:1; 30:1). Released calcein was quantified by 
spectrophotometry and the degree of lysis determined. Assays were performed in triplicates 
with means and standard deviations displayed in line graphs. (a) CAM assays were performed 
with CD5-purified CLL cells or PBMCs from P11 used as APCs. (b-d) CAM assays were performed 
with PBMCs from three other CLL patients (P5, P1, P7) used as APCs. (e) CAM assay was 
performed with PBMCs of CLL patient P3 that were pulsed with EBNA3C-#2-AgAbs against CD19, 
CD20, CD21, or CD22, respectively. 
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2.3.5.2. CD107a expression on effector T cells 
 
T cell-mediated cytotoxicity can be mediated through the exocytosis of secretory 
lysosomes that include perforin and granzymes. These cytoplasmic granules are 
enveloped by a lipid bilayer in which LAMPs are expressed. These include 
CD107a, which is a surrogate marker for CTL effector function. The expression of 
CD107a on patient-derived EBNA3C-specific CD4+ T cell lines was assessed upon 
activation with EBNA3C-AgAb-treated target cells. The percentage of CD107a-
expressing CD4+ T cells was monitored at different time points (0 – 8 h) using 
flow cytometry analysis. In P11, CD4+ T cells showed increased net positivity for 
CD107a when they were co-cultured with autologous PBMCs pulsed with 
EBNA3C-#2 (45 % at 6 h) and -#3 AgAbs (26 % at 6 h), indicating endowment 
with potential cytotoxic functions. Target cells incubated with the control native 
antibody, with the EBNA3C-#1-conjugated AgAb, or in mock medium did not 
induce any specific CD107a expression (Figure 22a). The line graph in Figure 
22b shows a time-dependent increase of CD107a expression on CD4+ T cells after 
stimulation with APCs that were treated with EBNA3C-#2 or -#3 AgAbs. The 
proportions of CD107a-expressing EBNA3C-specific CD4+ cells that were ex vivo 
expanded from each patient are summarized in Table 5. 
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(a) Flow cytometry plots showing CD107a expression on CD4+ T cells (Q2) at 0 – 8 h after co-
culture with autologous PBMCs previously incubated with anti-CD20 mAb-, anti-CD20+EBNA3C-
#1, -#2, or -#3 AgAb-pulsed, or in mock medium. (b) Line graph showing the summarized time-
dependent evolution of CD107a-expressing CD4+ T cells after stimulation. 
 
 
2.3.5.3. GrB secretion from effector T cells 
 
Having demonstrated that the cytolytic activity of EBNA3C-specific CTLs 
expanded from CLL patients is abolished through the use of CMA, and that a 
distinct percentage of these T cells express CD107a upon stimulation with 
EBNA3C-AgAb-pulsed APCs, direct secretion of GrB from activated effectors was 
quantified. CLL cells (either isolated or in PBMC pool) were treated with 
EBNA3C-AgAbs and mixed with autologous EBNA3C-specific CD4+ T cells at E:T = 
5:1. As a negative control, target cells were incubated with the respective non-
conjugated antibodies, or in mock solution. Released GrB was measured by 
ELISA. The assay results indicate that GrB is strongly secreted upon AgAb 
stimulation at much higher levels than IFN-γ. As observed with the release of 
IFN-γ from activated T cells, the intensity of GrB release varied across the CLL 
subject pool (summarized in Table 5). In Figure 23, GrB assay results of four 
EBNA3C-specific CD4+ T cell lines (P4, P11, P10, P6) are presented. The patient-
restricted EBNA3C segment specificities previously recorded in IFN-γ assays 
could be confirmed in these assay series. 
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Figure 23: Patient-derived EBNA3C-specific CD4+ T cells release GrB upon treatment with 
AgAbs. As target cells, 5 x 104 CLL cells (pure or in PBMC pool) were pulsed with EBNA3C-AgAbs, 
antibody controls, or mock medium. Released GrB serves as a surrogate marker for CTL function 
and was quantified by ELISA upon co-culture with autologous EBNA3C-specific CD4+ T cells for 
16 h. Assays were performed in triplicates with means and standard deviations displayed in bar 
charts. (a) Purified CLL or PBMCs from P11 were used as APCs. (b-d) PBMCs from three 
additional CLL patients (P9, P10, P4) were used as APCs. 
 
 
2.3.6. Killing efficiency of EBNA3C-specific CD4+ T cells does not correlate with 
the release of IFN- and GrB 
 
EBNA3C-specific CD4+ T cells expanded from CLL subjects were found to have 
stronger IFN- and GrB responses when co-cultured with EBNA3C-AgAb-treated 
autologous LCLs (as compared to EBNA3C-AgAb-pulsed CLL cells) as APCs. As an 
example, ex vivo expanded CD4+ T cells specific to EBNA3C-#3 derived from P6 
were co-cultured together with EBNA3C-AgAb-treated autologous LCLs or CLL 
cells in IFN- and GrB release assays. The results show highly increased IFN- 
and GrB secretion by nearly six-fold and three-fold, respectively, when EBNA3C-
#3 is presented on autologous LCLs instead of CLL cells (Figure 24a-b). This 
phenomenon was also observed in other EBNA3C-specific T cell lines expanded 
from CLL subjects (data not shown). Interestingly, T cell-mediated killing of 
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EBNA3C-AgAb-pulsed autologous LCLs and CLL cells did not significantly differ 
despite the tremendous difference in IFN- and GrB release (Figure 24c). A 
repeated-measure ANOVAs with the within subject factor ǲcell typeǳ (PBMC vs. 
LCL) and the between subject factor ǲtreatmentǳ (mAb CD20 vs. anti-CD20+ 
EBNA3C-#3) was conducted. The analysis of this experiment yielded only a 
significant main effect of ǲtreatmentǳ with anti-CD20+EBNA3C-#3, F(1, 4) = 
137.85, p < .001, indicating that AgAbs compared to native antibody control 
treatment led to higher killing responses in both cell-lines. No other main effects 
or interactions reached significance (p > .05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Increased release of IFN-γ and GrB from EBNA3C-specific CD4+ T cells induced 
through EBNA3C-AgAb-pulsed LCLs does not correlate with enhanced target lysis efficacy 
as compared to CLL cells. IFN- release and cytotoxicity assays were individually performed 
with primary CLL and LCLs as APCs. (a) IFN- release assay was performed using 50 ng EBNA3C-
AgAbs or non-conjugated antibody. (b) same as (a) for GrB release assay. (c) same as (a) for 
calcein release cytotoxicity assay performed at E:T of 30:1 for 3 h. * Mean value was significantly 
different between the task demand categories (p < .05). Assays were performed in triplicates 
with means and standard deviations displayed in bar graphs. 
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2.3.7. Characteristics of patient-derived EBNA3C-specific CD4+ T cells: an 
overview 
 
Data characterizing patient-derived CD4+ EBNA3C-specific T cell cells by means 
of antigen specificity and CTL activity against AgAb-treated target cells are 
summarized in Table 5. The read-out values were obtained from IFN-γ, GrB, and 
CAM assays by using primary CLL cells treated with anti-CD20 AgAbs. Signals 
derived from samples that were treated with anti-CD20 mAb (negative control) 
were subtracted from the above mentioned read-out values. Thus, these 
numbers amount to the specific net effects of EBNA3C-specific CD4+ T cells 
against primary CLL cells treated with anti-CD20 AgAbs. T cell specificity 
against distinct EBNA3C epitopes was evaluated through the application of 
synthesized HLA class II-restricted EBNA3C peptides onto LCLs co-cultured 
with autologous EBNA3C-specific CD4+ T cells. CD107a expression on T cells 
was measured after stimulation with EBNA3C-AgAb-treated LCLs. 
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Table 5: Summarized characterization of EBNA3C-specific CD4+ T cells ex vivo expanded 
from CLL patients. The table indicates the antigen fragment (and epitope) specificity of CD4+ T 
cells derived from all CLL patients, the level of IFN-γ and GrB secretion, the magnitude of the 
cytotoxic response measured in calcein release and the CD107a expression profile upon 
stimulation with EBNA3C-AgAbs. In IFN-γ, GrB, and CAM assays, primary CLL cells were used as 
APCs. The IFN-γ response levels were split into high (> 2000 pg/mL), medium (500 – 2000 
pg/mL), and low (0 – 499 pg/mL). The GrB secretion levels were divided into high (> 20,0000 
pg/mL), medium (5,000 – 20,000 pg/mL), and low (0 – 4,999 pg/mL). The percentage of primary 
target cells that were killed by effector T cells at E:T = 30:1 in CAM assays was divided into high 
(> 50 %), medium (16 – 50 %), and low (5 – 15 %). The proportion of CD107a-expressing CD4+ T 
cells upon stimulation with EBNA3C-AgAb-treated autologous LCLs is displayed in %. CD4+ T cell 
specificities against HLA class II-restricted EBNA3C peptides were evaluated by the use of LCLs 
pulsed with the four synthesized EBNA3C peptides ENP, SDD, PPV, and AQE. n/d: not 
determined. 
 
T cell responses measured in IFN-γ release upon stimulation with AgAb-treated 
primary CLL cells was divided into high (> 2,0000 pg/mL), medium (500 –  
2000 pg/mL), and low (0 – 499 pg/mL) intensity. High level responses were 
detected in six (P3, P5, P6, P8, P11, P12), medium in three (P1, P4, P9), and low 
in three (P2, P7, P10) EBNA3C-specific CD4+ T cell lines. GrB secretion was 
assessed after incubation of CD4+ T cells with autologous EBNA3C-AgAb-pulsed 
primary CLL cells. The GrB response was divided into high (> 20,000 pg/mL), 
medium (5,000 – 20,000 pg/mL), and low (0 – 4,999 pg/mL) intensity. Along 
this line, high GrB responses were found in three (P4, P5, P11), medium in eight 
(P1, P2, P3, P6, P8, P9, P10, P12), and low in one (P7) subject(s). Direct target 
cell killing was evaluated using CAM release assays. Lysis of primary CLL cells 
was measured after a 3 h co-culture with autologous EBNA3C-specific CD4+ T 
cells at E:T = 30:1. The scale of T cell responses was compartmentalized in high 
CLL 
subject 
CD4+ T cell 
specificity 
(EBNA3C) 
IFN- 
release 
GrB 
release 
CAM 
release 
CD107a 
surface 
expression 
EBNA3C CD4+ 
T cell epitope 
specificity 
P1 -#2, -#3 medium medium high 49 % PPV 
P2 -#2, -#3 low medium high 22 % n/d 
P3 -#2, -#3 high medium high 20 % AQE 
P4 -#2, -#3 medium high high 14 % AQE 
P5 -#1, -#2 high high high 28 % PPV, SDD 
P6 -#3 high medium medium 45 % n/d 
P7 -#3 low low high 30 % n/d 
P8 -#2, -#3 high medium medium 59 % AQE 
P9 -#1, -#3 medium medium high 58 % n/d 
P10 -#3 low medium low 15 % n/d 
P11 -#1, -#2, -#3 high high medium 41% n/d 
P12 -#2 high medium medium 41 % SDD 
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(> 50 %), medium (16 – 50 %), and low (5 –15 %) target cell killing. Thus, direct 
target cell killing was shown to be high in seven (P1, P2, P3, P4, P5, P7, P9), 
medium in four (P6, P8, P11, P12), and low in one (P10) CLL subject(s). T cell 
surface expression of CD107a was evaluated on activated EBNA3C-specific CD4+ 
T cells using flow cytometry. In all patient cases, stimulation with EBNA3C-
AgAb-pulsed LCLs resulted in a distinct proportion of CD4+ T cells that express 
CD107a ranging from 14 to 59 % with an average value of 35 %. CD4+ T cell 
specificity against EBNA3C was further confirmed in four CLL patients (P1, P4, 
P5, P8) by the use of HLA class II-restricted EBNA3C peptides. Thus, specificity 
to AQE was identified in three, PPV in two and SDD in two CLL subjects. 
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3. DISCUSSION 
 
In this doctoral work, the results of a novel immunotherapy approach to redirect 
CLL patient-derived EBV-specific CD4+ CTLs against primary leukemic B cells 
labeled with EBV antigens are reported. For this purpose, the 
immunotherapeutic efficacy of antigen-armed antibodies, or AgAbs, which 
combine viral proteins with antibodies directed against mature B cell receptors, 
was investigated ex vivo. The chimeric fusion proteins are able to shuttle highly 
immunogenic large-sized EBV antigens into CLL cells followed by HLA class II 
presentation, which enabled recognition through EBV-specific CD4+ CTLs. The 
data clearly demonstrates that treatment of CLL cells with AgAbs stimulated the 
activation and expansion of CD4+ CTLs specific to EBV, a herpesvirus that infects 
the majority of the population. The treatment harnessed potent immune 
responses in all twelve therapy-naïve CLL subjects tested. In each case, patient-
derived primary CLL cells treated with AgAbs were killed by ex vivo expanded 
endogenous T cells, usually with very high efficacy. 
 
AgAbs directed against CD19, CD20, CD21, or CD22, conjugated with three 
different EBV EBNA3C antigen fragments, respectively, here referred to as 
EBNA3C-#1, -#2, and -#3, were generated in this work. In binding assays using 
flow cytometry, these chimeric proteins recognized B cells as efficient as 
unconjugated antibodies. The risk of potential non-specific off-target effects 
caused by the antibody moiety of AgAbs was assessed with control isotype anti-
mouse CD22 antibodies conjugated with EBNA3C segments. The control AgAbs 
neither showed binding to target cells nor induction of T cell activation. The 
occurrence of non-specific AgAb binding through the antibody Fc domain or 
other interactions can therefore be discriminated with these conjugates. The 
ability of large antigen-conjugated antibodies to induce HLA class II presentation 
of single viral epitopes on healthy B cells was tested using a CD4+ T cell clone 
specific to the EBNA3C epitope ENP. In IFN-γ assays, it was demonstrated that 
these large antigen attachments were efficiently vehicled into the B cells and 
subsequently recognized by these T cells. Importantly, ENP-specific T cells only 
recognized B cells that were pulsed with AgAbs that contain the ENP epitope 
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sequence in their EBNA3C segment. In contrast, antibodies conjugated with 
EBNA3C segments devoid by the ENP epitope failed to induce T cell activation. 
Further characterization was followed up by expanding EBNA3C-specific CD4+ T 
cells from a healthy donor through repetitive stimulation using APCs pulsed with 
EBNA3C-AgAbs. The established T cell line elicited a strong IFN-γ response and 
efficient perforin/GrB-mediated cytotoxicity against autologous APCs only when 
they were pre-loaded with EBNA3C-#2 AgAbs, which indicates that these T cells 
were specific to this particular EBNA3C segment. APCs that were not pulsed or 
pre-loaded with EBNA3C-#1-, or EBNA3C-#3-conjugated antibodies did not 
induce any specific T cell responses.  
Having evaluated the functionality and efficiency of these AgAbs on cells from 
healthy donors, the study was proceeded with the recruitment of blood samples 
from twelve chemotherapy-naïve patients with CLL. In all tested CLL samples, 
rapid ex vivo expansion of memory CD4+ T cells was monitored through the 
repetitive stimulation with autologous APCs that were pulsed with EBNA3C-
AgAbs. Using IFN-γ release assays, it was shown that, in all patients, these T cells 
were specific against EBNA3C. Therefore, EBNA3C-AgAbs were able to induce 
the outgrowth of endogenous EBNA3C-specific CD4+ T cells in all tested subjects 
underlining the antigen’s high coverage in the global population, which is in line 
with high response frequencies of CD4+ T cells specific to EBNA3C. In nine 
subjects, co-expansion of CD3+ CD8+ and CD3+ CD4+ cells was observed. These 
two subsets were separated and individually tested in IFN-γ and cytotoxicity 
assays. The outcome clearly demonstrated that EBNA3C-specific T cell responses 
were confined to the CD4+ and not to the CD8+ T cell subset. The specificity of the 
CD8+ T cells remained unclear, however, they could be autoimmune in nature as 
previously described in CLL patients [223, 224]. The specificities of the expanded 
CD4+ T cells were characterized more precisely using a set of four (out of 
numerous) HLA class II-restricted EBNA3C peptides. A specific response was 
found against three of these peptides in six out of twelve CLL subjects. It has to 
be noted that these tests were confined to a limited number of EBNA3C peptides, 
therefore EBNA3C epitope-restricted specificity could not be determined in each 
expanded T cell line. 
 DISCUSSION  
 
 64 
CD4+ T cells are more commonly known as helper cells that facilitate CD8+ T cell 
function, however, multiple clinical studies have emphasized that CD4+ T cells 
can exert cytotoxicity against tumor targets, and can be more efficient at tumor 
rejection than CD8+ subsets [225]. Using CAM assays, it was unequivocally 
demonstrated that primary CLL cells pulsed with EBNA3C-AgAbs were 
specifically killed by autologous EBNA3C-specific CD4+ T cells in all patient 
samples. Thereby, the tumor cells were more sensitive to cytolysis at elevated 
E:T ratios. CTL activity was ascribed to the perforin/GrB-mediated pathway as T 
cell-mediated cytotoxicity was blocked by CMA, a compound that inhibits 
granule exocytosis. This finding was additionally confirmed by the induction of T 
cell-mediated secretion of GrB and cell surface expression of CD107a after co-
incubation with AgAb-pulsed APCs. The level of GrB release appeared to be much 
stronger than the secretion of IFN-, which happened to be very low in a few 
cases. In this context, it has previously been reported that T cells with CTL 
function do not always release IFN- whereas non-cytotoxic T cells may secrete 
IFN- [226]. Nevertheless, IFN- has been shown to be critical for tumor rejection 
in preclinical trials dealing with adoptive T cell therapies [227], and often, 
tumors were even eliminated in the absence of lytic mechanisms [228]. 
Reciprocally, CTLs with IFN- deficiency rarely rejected tumors [229]. For direct 
tumor cell lysis, however, GrB release may be a more specific indicator than IFN-
 secretion, even though secreted GrB cannot always be correlated to target cell 
lysis [230]. Hence, the proteolytic activity of GrB can be inhibited by serpin 
proteinase inhibitor 9 (PI-9)-expressing lymphoma cells. In addition, CLL cells 
frequently over-express Bcl-2, an anti-apoptotic protein that inhibits perforin-
dependent pathways [231]. Both mechanisms are considered to be immune 
escape strategies. Direct target cell lysis assays, as performed with CAM, are 
therefore indispensable. Moreover, GrB release assays using ELISA are limited by 
a uni-parametric quantification, which provides no information on the 
proportion of effector cells that exert CTL function. CD107a serves as a surrogate 
marker for degranulation mediated by transient lysosomal fusion to the cellular 
membranes and release of granule compounds. In this context, flow cytometric 
single cell-based analyses were performed to evaluate the proportion of CD107a-
expressing cells in each CD4+ T cell line upon stimulation with AgAb-pulsed 
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APCs. The outcome of the CD107a assays suggested that, on average, nearly one 
third of the CD4+ T cells has CTL function. Along this line, it remains to be 
determined whether CD107a-negative CD4+ T cells contribute to the elimination 
of CLL cells through helper function. 
Primary CLL cells, as compared to LCLs, generally induced much lower levels of 
T cell-mediated IFN- and GrB release after stimulation with AgAbs. On one 
hand, peripheral blood CLL cells were demonstrated to possess limited capacity 
to present soluble antigen despite high expression levels of HLA class II 
molecules [232]. On the other hand, LCLs are known to function as efficient APCs 
with high expression rates of target (CD19, CD20, CD21, CD22) and presentation 
molecules (HLA class II) [233, 234]. Moreover, the absolute number of these 
molecules can be much higher on LCLs due to their large cell sizes. Despite the 
prominent differences obtained in IFN- and GrB release assays, CAM 
experiments showed that CLL cells and LCLs, respectively treated with AgAbs, 
were killed with similar efficiency by EBNA3C-specific CD4+ T cells. This may 
result from the observation that LCLs express viral and cellular anti-apoptotic 
proteins [235], which may limit the efficacy of CTL responses. However, EBV-
specific T cells have previously been shown to eliminate post-transplant 
lymphoproliferative disorders (PTLD) in vivo [236], tumors that show similar 
gene expression patterns as observed in LCLs [237, 238]. Taken together, no 
correlation was found between the level of cytotoxicity, the intensity of IFN-γ 
responses, and the investigated clinical parameters including WBC, time from 
diagnosis, CD4/CD8 ratio, and the CLL cell burden in the peripheral blood.   
CLL cells have frequently been described as refractory to immune responses 
mediated by rituximab, an anti-CD20 mAb [239, 240]. The resistance to 
rituximab might derive from increased CD20 internalization rates that have most 
incisively been observed in CLL followed by MCL, FL, and finally DLBCL, which 
displayed very little internalization [52, 241]. This phenomenon may explain 
why CLL treatment needs approximately a six-fold higher dose of rituximab than 
other lymphoid tumors [55, 242, 243]. Moreover, transient CD20 
downmodulation was reported in a certain number of CD20-positive CLL 
patients after chemoimmunotherapy with rituximab [200]. Hence, there is a 
strong need for novel immunotherapies that combat these immune evasion 
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strategies. Our treatment with AgAbs will benefit from elevated internalization 
rates that potentially lead to increased antigen presentation on CLL cells and 
possibly other B lymphoma cells. The efficacy of AgAbs may further be enhanced 
by abolishing Fc-associated effector functions through the insertion of specific 
mutations into the Fc domain [244]. Moreover, our panel of AgAbs addresses 
multiple target cell receptors with similar efficiency. A consecutive tailored 
treatment may therefore offer alternative options in cases of downregulated 
target markers. The use of large antigen conjugations harbors the potential for a 
treatment that is accessible for a large cohort of patients with diverse HLA 
haplotypes. Concurrently, haplotype-matching epitope restrictions do not need 
to be identified in individual CLL patients. The risk of tumor escape through 
exhaustion of single peptide-specific T cell clones is diminished through the 
potential expansion of polyclonal T cells.  
In the treatment of relapsed or refractory CLL, tyrosine kinase inhibitors such as 
ibrutinib and idelalisib have seized powerful roles with remarkable clinical 
activity. Both inhibitors target signaling molecules downstream of BCRs but do 
not engage in direct T cell interaction. In fact, idelalisib inhibits the production of 
inflammatory cytokines [245]. Ibrutinib, on the other hand, amplifies Th1-based 
immune responses and cytokine production by subverting Th2 immunity [246]. 
A combination treatment of tyrosine kinase inhibitors and AgAbs might 
potentiate the immune response against CLL cells, and may therefore be a 
promising strategy. In patients with CLL, there is evidence of increased 
expression of PD-1 and CTLA-4 in the global T cell population [247, 248]. In this 
context, PD-1- or CTLA-4-blocking antibodies may additionally increase anti-
tumor immune responses through modulating the signaling cascade of these co-
stimulatory and -inhibitory receptors. However, it is unknown whether these 
checkpoint-blocking antibodies will also show benefits in a combination 
treatment with AgAbs since EBV-specific T cells have been reported to be PD-1-
negative in CLL [216]. T cell exhaustion might additionally be caused by 
recruited suppressor cells, which secrete elevated levels of transforming growth 
factor  (TGF-) [249]. In CLL, T cell dysfunction with impaired immunological 
synapse formation has been reported in both CD4+ and CD8+ T cells [64, 250-
252], which, however, can be restored by using lenalidomide, an 
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immunomodulatory drug [64]. Regarding this, our results may appear to be 
contradictory to the current view of immune suppression in CLL. These studies, 
however, were restricted to the global T cell population in CLL patients. Counter-
intuitively, EBV-specific CD8+ T cells from CLL patients have recently been 
described as functionally intact with respect to immune synapse formation, 
cytokine production, and cytotoxicity, challenging the concept of global T cell 
dysfunction in CLL [216]. The same phenomenon was observed in CMV-specific 
CD8+ T cells from CLL patients [253]. It is unclear, whether these T cell subsets 
represent an exception or whether T cell exhaustion is indeed more 
heterogeneous in CLL than previously assumed [216].  
A potential limitation of our study is the restriction to therapy-naïve patients 
because the efficacy of treatment does critically depend on the presence of CTLs 
in patients with CLL. For this reason, a lower therapy efficacy can be assumed in 
patients that have been subjected to intensive cytotoxic treatment. Concerns may 
also derive from the presence of pre-existing antibodies against EBNA3C 
peptides in the serum of patients, which could build complexes with AgAbs. This 
effect might decrease the efficiency of the treatment through impaired targeting 
of the CLL cells. In our ex vivo study where human serum was constantly used 
during T cell maintenance and stimulation, we found no evidence of neutralized 
AgAbs that lost their effects. Moreover, it has been described that IgG titers 
against EBV decrease with progressive hypogammaglobulinemia in CLL, with 
complete seroconversion from positive to negative EBV IgG values observed in 
several patients [254].   
 
Another study of our laboratory currently investigates the in vivo efficacy of 
AgAbs using a preclinical syngeneic mouse model of B cell lymphoma. In the 
experimental setup, BALB/c mice are infected with the murine cytomegalovirus 
(mCMV) in order to induce a primary anti-viral T cell immune response. B cell 
lymphoma cells are then injected into the animals, which are subsequently 
challenged by antibodies conjugated with mCMV epitopes. Thus, multiplied CTL 
clones specific to mCMV are expected to eradicate malignant B cells in vivo 
through the repetitive application of AgAbs.  Together with the work presented 
here, this animal study will demonstrate the therapeutic potential of AgAbs. 
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Concurrently, our laboratory also investigates the potential of AgAbs in active 
immunization. Previously, vaccination of DCs using anti-DEC-205 antibodies 
conjugated with EBNA1 induced the production of anti-EBNA1 antibodies and 
primed EBNA1-specific IFN-γ-secreting CD4+ and CD8+ T cells in a subset of 
immunized mice. DEC-205 receptors internalized the antigen-conjugated 
antibody and presented the antigen to both CD4+ and CD8+ T cells through cross-
presentation [169]. Similarly, targeting of LcrV virulence protein from Y. pestis to 
DCs elicited combined humoral and cellular immunity with protection against 
pneumonic plague in mice [255, 256]. Although mature DCs were described to be 
superior in priming naïve T cells, B cells might additionally amplify immune 
responses, which were induced through the vaccination of DCs [167].  
Beyond, AgAbs that deliver antigen to HLA class I and II molecules are a highly 
interesting matter since a combined attack of CD4+ and CD8+ T cells may be 
favorable to achieve the strongest tumor rejection possible. Hitherto, HLA class I 
presentation of exogenous antigens has traditionally been considered as a typical 
property of DCs [257, 258]. Cross-presentation, which describes the processing 
and presentation of extracellular antigens with HLA class I molecules to CD8+ T 
cells, has also been described for B cells [259, 260]. In our study, however, no 
evidence was found that memory EBNA3C-specific CD8+ T cells were reactivated 
and expanded ex vivo from CLL subjects. Along this line, calreticulin (CRT) has 
been described as a potential mediator and enhancer of exogenous antigen 
cross-presentation [261, 262]. This endoplasmic reticulum (ER)-localized 
chaperone functions as a co-factor in the intracellular assembly of HLA class I 
molecules [263]. Therefore, AgAb-CRT fusion constructs may have the potential 
to generate strong anti-tumor immunity mediated by CD8+ T cells. 
 
In conclusion, AgAbs represent a novel approach to treat CLL, a slow progressing 
tumor that allows time for the generation of T cell-mediated immune responses. 
Long-segment AgAbs were shown to be very powerful in inducing potent CTL 
responses against CLL cells ex vivo in all tested patient blood samples. The 
results of the study warrant the inception of clinical trials in order to evaluate its 
clinical benefits in patients with CLL. 
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4. MATERIAL AND METHODS 
 
4.1. Material 
 
4.1.1. Cells and viruses 
 
Bacteria, mammalian cell lines (besides primary material) and viruses used in 
this study are listed in Table 6. 
 
Table 6: List of bacteria, commercial mammalian cell lines, and viruses with description. 
Name 
Organism / 
virus 
Description 
DH5 E. coli 
Competent bacterial cells; F– ΦͺͲlacZΔMͳͷ ΔȋlacZYA-argF) U169  
recA1 endA1 hsdR17 (rK–, mK+) phoA supEͶͶ ɉ– thi-1 gyrA96 relA1 
(InvitrogenTM) 
HEK293 H. sapiens 
Human embryonic kidney cells; adenovirus type 5 DNA from left end 
of the viral genome (ATCC® RF32764)  
B95.8 EBV Epstein-Barr virus strain B95.8 
 
 
4.1.2 Enzymes 
 
Enzymes used in this work are listed in Table 7.  
 
Table 7: List of enzymes with description. 
Name Concentration Supplier 
Catalogue 
number 
DNase I (RNase-free) 50 U/ɊL Thermo Fisher Scientific EN0523 
EcoRI 10 U/ɊL Thermo Fisher Scientific ER0271 
HindIII 10 U/ɊL Thermo Fisher Scientific ER0501 
Phosphatase, alkaline (AP) 
from calf intestine 
1 U/ɊL Roche 10713023001 
Phusion® High Fidelity 
DNA Polymerase 
2 U/ɊL New England BioLabs® M0530S 
RNase A 100 mg Roche 3335399001 
T4 DNA ligase 5 U/ɊL Thermo Fisher Scientific EL0011 
 
 
4.1.3. Commercial antibodies 
 
Commercial antibodies used in this work are listed in Table 8. 
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Table 8: List of antibodies with detailed description. FITC: fluorescein isothiocyanate; PE: 
phycoerythrin; PE-Cy5: phycoerythrin-cyanin 5; APC: allophycocyanin. 
Name Clone Reactivity Isotype Conjugation Supplier 
Catalogue 
number 
CD3  
BW264/5
6 
human 
mouse 
IgG2a 
FITC 
Miltenyi 
Biotec 
130-080-401 
CD4 RPA-T4 human 
Mouse 
IgG1 
PE eBioscience 12-009-41 
CD4  RPA-T4 human 
Mouse 
IgG1 
PE-Cy5 eBioscience 15-0049-42 
CD5 UCHT2 human 
Mouse 
IgG1 
PE eBioscience 12-059-41 
CD8a  SK1 human 
Mouse 
IgG1 
PE BioLegend 344706 
CD19 LT19 human 
Mouse 
IgG1 
FITC 
Miltenyi 
Biotec 
130-091-328 
CD21 THB-5 human 
Mouse 
IgG2a 
unconjugated Santa Cruz sc-18857 
CD107a eBioH4A3 human 
Mouse 
IgG1 
FITC eBioscience 11-1079-41 
HLA-DR, 
DP, DQ 
Tu39 human 
mouse 
IgG2a 
FITC 
BD 
Pharmingen 
2009-09-14 
IgG1 iso-
type ctrl 
unknown mouse 
Mouse 
IgG1 
unconjugated Santa Cruz Sc-3877 
IgG2a iso-
type ctrl 
unknown mouse 
Mouse 
IgG2a 
unconjugated Invitrogen MG2A00 
IgG2a  m2a-15F8 mouse 
Rat 
IgG1 
PE eBioscience 12-4210-82 
PE 
Microbeads 
- - 
Mouse 
IgG1 
Microbeads 
Miltenyi 
Biotec 
130-048-801 
 
 
4.1.4 Molecular-weight size marker 
 
DNA and protein standards used in this work are described in Table 9. 
 
Table 9: Molecular-weight size marker. 
Name Supplier 
Catalogue 
number 
1 Kb Plus DNA Ladder 
Thermo Fisher 
Scientific 
10787018 
PageRulerTM Prestained Protein Ladder, 10 to 180 kDa 26616 
SpectraTM Multicolor High Range Protein Ladder, 40 to 300 kDa 26625 
 
 
4.1.5. Oligonucleotides 
 
Oligonucleotide primers shown in Table 10 were designed for plasmid-based 
cloning and sequence analysis of EBNA3C-AgAbs (mouse IgG2a anti-human 
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CD19, CD21, CD20, or CD22 + EBNA3C-#1, -#2, or -#3, respectively, and mouse 
IgG2a anti-mouse CD22 + EBNA3C-#1, -#2, or -#3, respectively). 
 
Table 10: Oligonucleotides used for cloning and sequencing of EBNA3C-AgAbs. FW/fwd: 
forward; RV: reverse; OL: overlap; var: variable region; const: constant region; HC: heavy chain; 
MoAHu: mouse anti-human; MoAMo: mouse anti-mouse. 
Lab 
ID 
Description Sequence 
289 pRK5 Primer ACCCCCTTGGCTTCGTTAG 
856 pRK5-seq2-A CCTAACCAAGTTCCTCTTTCAG 
1611 ENPinVIS4-SQFW GGACCATCCGTCTTCATCTTC 
1838 fwd_aHuCD19/20/21/22HC 
TCGATTGAATTCATGGCTGTCCTGGTGCT
GTT 
1986 FW_EcoRI_BERF3start 
TCGATTGAATTCATGGAATCATTTGAAGG
ACAG 
1987 RV_BERF3end_BERF4startOL 
CGCTTGCAGGTGCGATTGCTTGACAGCCC
GGCAG 
1988 FW_BERF3endOL_BERF4start 
GCCTGCCGGGCTGTCAAGCAATCGCACCT
GCAAG 
1989 RV_BERF4end_HindIII 
TGAGCAAGCTTTTAATCTAGCTCACTTTC
AGTG 
1990 RV_CD19HCend_EBNA3C(990_1/3)startOL 
CTGTCCTTCAAATGATTCTTTACCCGGAG
TCCGGGA 
1991 RV_CD19HCend_EBNA3C(993_2/3)startOL 
TCTTTTATGCCTCTTTTACCCGGAGTCCG
GGA 
1992 RV_CD19HCend_EBNA3C(993_3/3)startOL 
CTCCCTCATAAACATACGTTTACCCGGAG
TCCGGGA 
1993 FW_CD19endOL_EBNA3C(990_1/3)start 
TCCCGGACTCCGGGTAAAGAATCATTTGA
AGGACAGGG 
1994 RV_EBNA3Cend(990_1/3)_Stop_HindIII 
TGAGCAAGCTTTCACCGCGCGTGATATGG
A 
1995 FW_CD19endOL_EBNA3C(993_2/3)start 
TCCCGGACTCCGGGTAAAAGAGGCATAAA
AGAACAC 
1996 RV_EBNA3Cend(993_2/3)_Stop_HindIII 
TGAGCAAGCTTTCATTGCATTTGTGTAAT
TTC 
1997 FW_CD19endOL_EBNA3C(993_3/3)start 
TCCCGGACTCCGGGTAAACAAGAACCAAG
TTCACAC 
1998 RV_EBNA3Cend(993_3/3)_Stop_HindIII 
TGAGCAAGCTTTCAATCTAGCTCACTTTC
AGTG 
1999 
RV_MoAHuCD19HC 
+overlap_EBNA3C(964-(1524) 
CGCAACCAAGGGTCCACGTTTACCCGGAG
TCCGGGA 
2000 
RV_MoAHuCD19HC 
+overlap_EBNA3C(964-(1524) 
TGGATTTTCATTAGGTGGTTTACCCGGAG
TCCGGGA 
2001 
RV_MoAHuCD19HC 
+overlap_EBNA3C(1465-(2016) 
CGGTGGCGTAGGCTTGACTTTACCCGGAG
TCCGGGA 
2002 
RV_MoAHuCD19HC 
+overlap_EBNA3C(1957 - (2514) 
AATTTCACGACCAGCCCGTTTACCCGGAG
TCCGGGA 
2003 
RV_MoAHuCD19HC 
+overlap_EBNA3C(2455 - (2979) 
TGGACCCTGGGTGTGCCCTTTACCCGGAG
TCCGGGA 
2004 
RV_MoAHuCD19HC_overlap 
+EBNA3C(1-528) 
TGAGCAAGCTTTCAGGGAGATGTTAGAAG
CCAAT 
 MATERIAL AND METHODS  
 
 72 
 
 
 
2005 
FW_MoAHuCD19HC_overlap 
+EBNA3C(469-1023) 
TCCCGGACTCCGGGTAAACGTGGACCCTT
GGTT 
2006 
RV_MoAHuCD19HC_overlap 
+EBNA3C(469-1023) 
TGAGCAAGCTTTCAGTTCTGGATTACGTG
TTCTT 
2007 
FW_MoAHuCD19HC_overlap 
+EBNA3C(964-1524) 
TCCCGGACTCCGGGTAAACCACCTAATGA
AAATCCA 
2008 
RV_MoAHuCD19HC_overlap 
+EBNA3C(964-1524) 
TGAGCAAGCTTTCAATCGTCGTACACAAC
ACA 
2009 
FW_MoAHuCD19HC_overlap 
+EBNA3C(1465-2016) 
TCCCGGACTCCGGGTAAAGTCAAGCCTAC
GCCACCG 
2010 
RV_MoAHuCD19HC_overlap 
+EBNA3C(1465-2016) 
TGAGCAAGCTTTCAGCGAGGCGTTGTAGG
CTG 
2011 
FW_MoAHuCD19HC_overlap 
+EBNA3C(1957-2514) 
TCCCGGACTCCGGGTAAACGGGCTGGTCG
TGAAAT 
2012 
RV_MoAHuCD19HC_overlap 
+EBNA3C(1957-2514) 
TGAGCAAGCTTTCATCCATCCCACTGAGG
TGG 
2013 
FW_MoAHuCD19HC_overlap 
+EBNA3C(2455-2979) 
TCCCGGACTCCGGGTAAAGGGCACACCCA
GG 
2014 
RV_MoAHuCD19HC_overlap 
+EBNA3C(964-2016) 
TGAGCAAGCTTTCAGCGAGGCGTTGTAGG 
2015 
FW_MoAHuCD19HC_overlap 
+EBNA3C(1957-2979) 
TCCCGGACTCCGGGTAAACGGGCTGGTCG
TG 
2037 see oligo 1988, alternative 
CTGCCGGGCTGTCAAGCAATCGCACCTGC
A 
2038 see oligo 1988 w/o overlap on 5' to BERF3 AGCAATCGCACCTGCA 
2039 
alternative to oligo 1989, last 18bp of BERF4 
missing 
TGAGCAAGCTTTTAGGATGCATCGTAGTC
AGTCT 
2040 see oligo 2039 w/o overlap on 5' end GGATGCATCGTAGTCAGTCT 
2041 see oligo 1989 w/o overlap on 5' end TTAATCTAGCTCACTTTCAGTG 
2067 fwd at end of MoAHuCD19-19HC (IgG2a) TACAGCAAGCTGAGAGTGGAA 
2085 fw primer EBNA3C CATCCAGACGTTGCTGCT 
2418 
FW_MoAMoCD19HC_var(B919) + 
MoAHuCD19HC_const_OL(B1201/B1302) 
TCGATTGAATTCATGAGATGGAGCTGTAT
CATT 
2419 
RV_MoAMoCD19HC_var(B919) + 
MoAHuCD19HC_const_OL(B1201/B1302) 
CGATGGGGCTGTTGTTTTGGCTGAGGAGA
CTGTGAGAGTGGT 
2420 
FW_MoAMoCD19HC_var(B919)_OL + 
MoAHuCD19HC_const(B1201/B1302) 
ACCACTCTCACAGTCTCCTCAGCCAAAAC
AACAGCCCCATCGGTC 
2433 FW_EBNA3C(1-1023bp) 
TCGATTGAATTCATGGAATCATTTGAAGG
ACAG 
2434 RV_EBNA3C(1-1023bp) 
TGGCAGAAGCTTTCAGTGGTGATGGTGAT
GATGGTTCTGGATTACGTGTTC 
2435 FW_EBNA3C(964-2016bp) 
TCGATTGAATTCATGCCACCTAATGAAAA
TCCATATCAC 
2436 RV_EBNA3C(964-2016bp) 
TGGCAGAAGCTTTCAGTGGTGATGGTGAT
GATGGCGAGGCGTTGTAGGCT 
2437 FW_EBNA3C(1957-2976bp) 
TCGATTGAATTCATGCGGGCTGGTCGTGA
AATT 
2438 RV_EBNA3C(1957-2976bp) 
TGGCAGAAGCTTTCAGTGGTGATGGTGAT
GATGATCTAGCTCACTTTCAGTGGATGC 
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4.1.6. Plasmids 
 
The plasmids listed in Table 11 were used for the recombinant production of 
mAbs and AgAbs. The GOIs were cloned into the mammalian expression vector 
pRK5. Except the plasmids encoding for light and heavy chains of native 
antibodies (B200, B233, B337, B343, B474, B482, B560, B581), all plasmids were 
newly designed and constructed in this work. 
 
Table 11: List of plasmids with detailed description. HC: heavy chain; LC: light chain; MoAHu: 
mouse anti-human; MoAMo: mouse anti-mouse; bp: base pairs; ORF: open reading frame. 
Lab ID Name Description 
B200 MoAHuCD21-LC Ɉ light chain of mouse anti-human CD21 mAb 
B233 MoAHuCD21-HC Mouse IgG2a heavy chain of mouse anti-human CD21 mAb 
B337 MoAHuCD19-LC Ɉ light chain of mouse anti-human CD19 mAb 
B343 MoAHuCD22-LC Ɉ light chain of mouse anti-human CD19 mAb 
B474 MoAHuCD19-HC Mouse IgG2a heavy chain of mouse anti-human CD19 mAb 
B482 MoAHuCD22-HC Mouse IgG2a heavy chain of mouse anti-human CD22 mAb 
B560 MoAHuCD20-HC Mouse IgG2a heavy chain of mouse anti-human CD20 mAb 
B581 MoAHuCD20-LC Ɉ light chain of mouse anti-human CD20 mAb 
B1199 
MoAHuCD22-HC  
+EBNA3C (1-1023 bp) 
Mouse IgG2a heavy chain of mouse anti-human CD22 mAb 
with EBNA3C ORF (1-1023 bp) attachment at the C-
terminus 
B1200 
MoAHuCD22-HC  
+EBNA3C (964-2016 bp) 
Mouse IgG2a heavy chain of mouse anti-human CD22 mAb 
with EBNA3C ORF (964-2016 bp) attachment at the C-
terminus 
B1201 
MoAHuCD22-HC  
+EBNA3C (1957-2976 
bp) 
Mouse IgG2a heavy chain of mouse anti-human CD22 mAb 
with EBNA3C ORF (1957-2976 bp) attachment at the C-
terminus 
B1202 
MoAHuCD19-HC 
+EBNA3C (1-1023 bp) 
Mouse IgG2a heavy chain of mouse anti-human CD19 mAb 
with EBNA3C ORF (1-1023 bp) attachment at the C-
terminus 
B1203 
MoAHuCD19-HC 
+ EBNA3C (964-2016 bp) 
Mouse IgG2a heavy chain of mouse anti-human CD19 mAb 
with EBNA3C ORF (964-2016 bp) attachment at the C-
terminus 
B1204 
MoAHuCD19-HC 
+ EBNA3C (1957-2976 
bp) 
Mouse IgG2a heavy chain of mouse anti-human CD19 mAb 
with EBNA3C ORF (1957-2976 bp) attachment at the C-
terminus 
B1205 
MoAHuCD20-HC 
+ EBNA3C (1-1023 bp) 
Mouse IgG2a heavy chain of mouse anti-human CD20 mAb 
with EBNA3C ORF (1-1023 bp) attachment at the C-
terminus 
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B1206 
MoAHuCD20-HC 
+ EBNA3C (964-2016 bp 
Mouse IgG2a heavy chain of mouse anti-human CD20 mAb 
with EBNA3C ORF (964-2016 bp) attachment at the C-
terminus 
B1207 
MoAHuCD20-HC 
+ EBNA3C (1957-2976 
bp) 
Mouse IgG2a heavy chain of mouse anti-human CD20 mAb 
with EBNA3C ORF (2057-2976 bp) attachment at the C-
terminus 
B1208 
MoAHuCD21-HC 
+ EBNA3C (1-1023 bp) 
Mouse IgG2a heavy chain of mouse anti-human CD21 mAb 
with EBNA3C ORF (1-1023 bp) attachment at the C-
terminus 
B1209 
MoAHuCD21-HC 
+ EBNA3C (964-2016 bp) 
Mouse IgG2a heavy chain of mouse anti-human CD21 mAb 
with EBNA3C ORF (964-2016 bp) attachment at the C-
terminus 
B1210 
MoAHuCD21-HC 
+ EBNA3C (1957-2976 
bp) 
Mouse IgG2a heavy chain of mouse anti-human CD21 mAb 
with EBNA3C ORF (2057-2976 bp) attachment at the C-
terminus 
B1301 
MoAHuCD19-HC 
+EBNA1 (1197-1866 bp) 
Mouse IgG2a heavy chain of mouse anti-human CD19 mAb 
with EBNA1 ORF (1197-1866 bp) attachment at the C-
terminus 
B1302 
MoAHuCD20-HC 
+EBNA1 (1197-1866 bp) 
Mouse IgG2a heavy chain of mouse anti-human CD20 mAb 
with EBNA1 ORF (1197-1866 bp) attachment at the C-
terminus 
B1303 
MoAHuCD21-HC 
+EBNA1 (1197-1866 bp) 
Mouse IgG2a heavy chain of mouse anti-human CD21 mAb 
with EBNA1 ORF (1197-1866 bp) attachment at the C-
terminus 
B1304 
MoAHuCD22-HC 
+EBNA1 (1197-1866 bp) 
Mouse IgG2a heavy chain of mouse anti-human CD22 mAb 
with EBNA1 ORF (1197-1866 bp) attachment at the C-
terminus in pRK5 
B1305 
EBNA1 (1197-1866 bp) 
+His-tag 
EBNA1 (1197-1866 bp) peptide with His-tag at C-terminus 
B1344 
EBNA3C (1-1023 bp)  
+His-tag 
EBNA3C (1-1023 bp) peptide with His-tag at C-terminus 
B1345 
EBNA3C (964-2016 bp)  
+His-tag 
EBNA3C (964-2016 bp) peptide with His-tag at C-terminus 
B1346 
EBNA3C (1957-2976 bp)  
+His-tag 
EBNA3C (1957-2976 bp) peptide with His-tag at C-
terminus 
 
 
4.1.7. Media and buffers 
 
4.1.7.1. Commercial media 
 
Commercial media used for tissue culture maintenance, plasmid DNA 
transfection and protein expression is listed in Table 12.  
 
Table 12: Commercial media. 
Name Supplier Catalogue number 
AIM V® Medium (1 x) 
gibco® by life technologiesTM 
31035025 
FreeStyleTM 293 Expression Medium 12338018 
Opti-MEM® I (1 x) 31985070 
RPMI Medium 1640 (1 x) 11875093 
RPMI Medium 1640, no phenol red 11835105 
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4.1.7.2. Supplements 
 
Media supplements listed in Table 13 were used for the formulation of complete 
media. 
 
Table 13: Supplements used for the formulation of complete media. 
Name Supplier 
Catalogue 
number 
Amphotericin B (250 g/mL) gibco® by life technologiesTM 15290026  
Ampicillin, stock solution:  
100 mg/mL in 50 % EtOH 
Serva 13399 
Fetal bovine serum (FBS) Seraglob – Serves Cell Culture S3500 
Gentamicin (50 mg/mL) 
gibco® by life technologiesTM 
15750037 
HEPES Buffer Solution (1 M) 15630090 
L-Glutamine 200 mM (100 x) 25030081 
MEM NEAA Solution (100 x) 11140035 
Sodium Pyruvate 100 mM (100 x) 11360070 
 
 
4.1.7.3. Formulated complete media 
 
The formulation recipe for LCL medium, T cell medium and LB medium is 
described in Table 14. LB medium and LB medium agar was sterilized by 
autoclaving for 20 min at 15 psi (1.05 kg/cm2) on liquid cycle. 
 
Table 14:  Formulation of complete media. 
Name Composition 
LCL medium 
RPMI Medium 1640 supplemented with 10 % HS (v/v), 2 mM L-glutamine, 10 
mM sodium pyruvate, 1 % non-essential amino acids (v/v), 1.25 g/mL 
amphotericin B, 50 g/mL gentamicin 
T cell medium 
AIM V® Medium supplemented with 10 % HS (v/v), 2 mM L-glutamine, 10 
mM HEPES, 50 g/mL gentamicin, 10 g/mL ciprofloxacin 
LB medium 
10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl in deioinized H2O, pH is 
adjusted to 7.0 with 5 N NaOH 
LB medium agar 32 g/L LB agar, 5 g/L NaCL in deioinized H2O 
 
 
4.1.7.4. Buffers and solutions 
 
The formulation recipe for buffers and other solutions is described in Table 15. 
Concentrated solutions were diluted in Milli-Q H20. 
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Table 15: Composition of buffers and other solutions. 
Name Composition 
ACK buffer 0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM EDTA 
Blotting buffer (1 x) 25 mM Tris, 150 mM glycine, 10 % (v/v) methanol 
DNA loading buffer (10 x) 0.25 % (w/v) bromphenol blue, 40 % (w/v) sucrose 
FACS buffer 1 % (w/v) BSA in PBS 
MACS buffer 0.5 % (w/v) BSA, 2mM EDTA in PBS 
Polyacrylamide separating gel 
(7.5 %) 
335 mM Tris (pH 8.9), 25 % (v/v) acrylamide stock, 3.3 mM 
EDTA, add freshly 100 L 10 % (w/v) APS and 10 L TEMED 
per each 10 mL 
Polacrylamide separating gel 
(12.5 %) 
335 mM Tris (pH 8.9), 42 % (v/v) acrylamide stock, 3.3 mM 
EDTA, add freshly 100 L 10 % (w/v) APS and 10 L TEMED 
per each 10 mL 
Polyacrylamide stacking gel 
(4.5 %) 
125 mM Tris (pH 6.8), 15 % (v/v) acrylamide stock, 4 mM 
EDTA, add freshly 15 L 10 % (w/v) APS and 5 L TEMED per 
each 2 mL 
PBS (10x) 
400 g (w/v) NaCl, 10 g (w/v) KCl, 72 g (w/v) Na2HPO4, 12 g 
(w/v) KH2PO4 
PBS-Tween-20 (PBS-T) (10 x) PBS (10 x), 1 % (v/v) Tween-20 
PEI 10x (10 mg/mL) 
0.5 g PEI in 50 mL H20 final volume, heat at 37 °C to dissolve 
PEI, cool down, adjust to pH 7, filter with 0.22 um pore size, 
aliquot, store at 4°C 
Phosphate buffered saline 
(PBS) (10 x) 
1.37 M NaCl, 27 mM KCl, 100 mM Na2HPO4, 20 mM KH2PO4 
Protein loading buffer (4 x) 
200 mM Tris HCl pH 6.8, 8 % (v/v) SDS, 40 % (w/v) glycine, 0.4 
% (w/v) bromphenol blue (+/--mercaptoethanol) 
RIPA buffer (5 x) 
750 mM NaCl, 2.5 % (v/v) NP40, 5 % (w/v) sodium 
deoxycholate, 0.5 % (v/v) SDS, 25 mM EDTA, 100 mM Tris HCl, 
pH 7.5 
Sodium acetate (NaOAc) 3 M (w/v) C2H3NaO2 in H2O 
SDS running buffer (10 x) 250 mM Tris, 1.92 M glycine, 1 % (v/v) SDS, pH 8.5 - 8.8 
Skimmed milk buffer (3 %) 3 % (w/v) skimmed milk powder in PBS-T 
TAE (50 x) 2.0 M Tris, 0.05 M EDTA, 1.0 M acetic acid 
TE buffer (1 x) 10 mM Tris pH 8.0, 1 mM EDTA pH 8.0 
 
 
4.1.8 Kits 
 
Kits for human cytokine ELISA assays and plasmid isolation using alkaline lysis 
are listed in Table 16. 
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Table 16: Kits for ELISA assays and plasmid isolation. 
Name Supplier 
Catalogue 
number 
Human IgG2a development (HRP)   
AffiniPure Goat Anti-Mouse IgG + IgM (H+L) Jackson ImmunoResearch Lab  115-005-068 
Mouse IgG2a anti-human CD21 (clone: THB-5) Santa Cruz sc-18857 
Anti-Mouse IgG HRP Conjugate  Promega W402B 
Human Granzyme B development kit (HRP) Mabtech 3485-1H-20 
Human IFN-γ EL)SA development kit (HRP) Mabtech 3420-1H-20 
Human IL-4 development kit (HRP) Mabtech 3410-1H-20 
Human TNF-Ƚ development kit ȋ(RPȌ Mabtech 3510-1H-20 
PureLinkTM HiPure Plasmid Maxiprep Kit Invitrogen K210007 
 
 
4.1.9. Chemicals 
An overview of chemicals used in this work is shown in Table 17. Chemical 
substances were of molecular biology grade. 
 
Table 17: List of chemicals. 
Name Supplier 
Catalogue 
number 
0.4 % trypan blue Sigma-Aldrich T8154 
2-mercaptoethanol Sigma-Aldrich M6250 
2-propanol Sigma-Aldirch 33539 
Acetic acid Sigma-Aldrich 71251 
Agarose Sigma-Aldrich A9539 
Ammonium chloride (NH4Cl) Sigma-Aldrich A9434 
Bovine serum albumin (BSA) Sigma-Aldrich A2153 
Ammonium persulfate (APS) Merck 1012010500 
BD OptEIATM TMB substrate reagent set BD Bioscience 555214 
Bromphenol blue Serva 15375.02 
Butanol Sigma-Aldrich B7906 
Calcein, AM (CAM) Thermo Fisher Scientific C3099 
Concanamycin A (CMA) Santa Cruz Biotechnology sc-202111 
DETACHaBEADTM CD19  Invitrogen  12506D 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich D2650 
dNTPs (dATP, dCTP, dGTP, dTTP) Roche 11969064001 
DynabeadsTM CD19 Pan B Invitrogen 11143D 
Ethanol Fisher Chemical E/0665DF/17 
Ethidium bromide (EtBr) Merck 1116150001 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich EDS 
Ficoll-PaqueTM PLUS GE Healthcare 17-1440-03 
Glucose Sigma-Aldrich D9434 
Glycine GERBU Biotechnik 200-272-2 
Hydrochloric acid (HCl) Sigma-Aldrich H1758 
LB Agar (Lennox L Agar) Invitrogen 22700-041 
Methanol Sigma-Aldrich 322415 
Monobasic potassium phosphate (KH2PO4) Sigma-Aldrich 1551139 
Polyethylenimine (PEI), branched Sigma-Aldrich 408727 
Potassium bicarbonate (KHCO3) Sigma-Aldrich 60339 
Phenol Carl Roth 203-632-7 
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Potassium chloride (KCl) Sigma-Aldrich P9333 
Protease inhibitor Sigma-Aldrich P8340 
Rotiphorese® Gel 30 (37,5:1) Carl Roth 3029.1 
Sodium acetate (C2H3NaO2) Sigma-Aldrich S2889 
Sodium chloride (NaCl) Fisher Chemical 7647-14-5 
Sodium dodecyl sulfate (SDS) 20 % solution MP Biomedicals 0219895790 
Sodium phosphate dibasic anhydrous (Na2HPO4) Sigma-Aldrich RES20908 
Skimmed milk powder Carl Roth 271-045-3 
Sucrose Carl Roth 4621.1 
Tetramethylethylenediamine (TEMED) Merck 1107320100 
Trizma® base Sigma-Aldrich T1503 
Triton® X-100 AppliChem A1388,1000 
Tween® 20 Sigma-Aldrich P1379 
Western Lightning® Plus-ECL PerkinElmer NEL103001EA 
 
 
4.1.10. Working devices and equipment 
 
Working devices and equipment applied in this study are listed in Table 18.  
 
Table 18: Working devices and machines used in this study. 
Name Supplier 
Catalogue 
number 
14 mL PP tube sterile greiner bio-one 187261 
5 mL polystyrene round-bottom tubes with cell-
strainer cap 12 x 75 mm style 
Falcon 351935 
AmershamTM HyperfilmTM ECL 
GE Healthcare Life 
Sciences 
 28906836 
BD FACSCaliburTM BD Biosciences 342975 
Cellstar® cell culture flasks 250 mL greiner bio-one 658170 
Cellstar® cell culture flasks 50 mL greiner bio-one 690160 
CellQuestTM Pro Software BD Biosciences - 
Corning EIA/RIA 1 x 8 StripwellTM 96 well plate Sigma-Aldrich CLS2592 
DNA/RNA UV-cleaner box, UVC/T-AR Biosan - 
FlowJo V.10.1 software FlowJo, LLC - 
Folder filters (Qual) Grade: 3 hw Munktell Ahlstrom E-1415 
Gammacell 1000 
Atomic Energy of Canada 
Ltd. 
- 
GraphPad Prism version 5.00 for Windows GraphPad Software Inc - 
Greiner Cryo.sTM vials Sigma-Aldrich V3135 
GSA rotor (RC5C) - - 
HeracellTM 150 incubator Thermo Fisher Scientific - 
HerasafeTM KS 12, class II biological safety 
cabinet 
Thermo Fisher Scientific - 
HeraeusTM Fresco 21 Centrifuge Thermo Scientific - 
HeraeusTM Megafuge 1.0 Heraeus - 
HeraeusTM Multifuge 3L Heraeus - 
HeraeusTM PicoTM 17 Microcentrifuge Thermo Fisher Scientific 75002410 
HydroFlexTM Tecan - 
INFORS HT Ecotron Infors AG - 
Injekt® 2mL Braun 4606027V 
Kern 572 Kern und Sohn GmbH - 
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Light inverted microscope DMIL-Led Leica Microsystems - 
LS columns (25 columns) Miltenyi Biotec 130-042-401 
MacVector software 15.1.1 (21) MacVector Inc. - 
Messer Griesheim Chronos Biosafe® - - 
Memmert Wasserbad memmert - 
MidiMACSTM Starting Kit (LS) Miltenyi Biotec 130-042-301 
Millex®-GS 0.22 m Merck Millipore Ltd. SLGS033SS 
MiniVE Vertical Electrophoresis System 
GE Healthcare Life 
Sciences 
80641877 
MultiDoc-It Digital Imaging System UVP - 
Multiskan Ex microplate photometer 
Thermo Electron 
Corporation 
- 
Nanodrop 2000 Fisher Scientific  S06497 
NEOJECT® ʹ͵G x ͳ ¼ǳ Dispomed® 10014 
pH-meter 766 Knick - 
Pipetboy acu 2 VWR 155017 
Power CAP 300 BioRad - 
Protran® Nitrocellulose Membrane Whatman Inc. - 
PTC-200 Peltier Thermo Cycler MJ Research 8252-30-0001 
Safe-lock microcentrifuge tubes 0.5/1.5/2.0 mL Eppendorf AG 
T8911/T9661/ 
T2795 
Sartorius BP toploader balance model BP110 Sigma-Aldrich Z267066 
Sonopulus HD2070 Bandelin Electronics - 
Sorvall RC-5C GMI 8327-30-0001 
SPSS version 24.0 for Windows IBM SPSS Statistics - 
SS34 rotor (RC5C) - - 
TProfessional Thermocycler Biometra 070-901 
Translluminator  UXDT-30SL-8E Biostep® - 
Ultrafree®-CL centrifugal device Merck Millipore UFC40GV0S 
Vivaspin® 20 centrifugal concentrator MWCO 
10,000 Da 
Sartorius VS2002 
Vortex-Genie 2 Scientific Industries SI-0236 
Western Lightning® plus ECL PerkinElmer - 
Zellkulturschale 100 TPP 93100 
Zellkulturschale 150 TPP 93159 
Zentrifugenröhrchen 15 TPP 91015 
Zellkulturtestplatte 24 TPP 92424 
Zentrifugenröhrchen 50 TPP 91050 
Zellkulturtestplatte 96U TPP 92697 
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4.2. Methods 
 
4.2.1. Construction of EBNA3C-AgAbs 
 
DNA sequences of anti-human CD19-, CD21-, CD22- [264], and CD20-specific 
antibodies were previously cloned [168]. EBNA3C-AgAbs were generated 
through seamless in frame fusion of one of three EBNA3C segments to the C-
terminus of the respective antibody heavy chain yielding EBNA3C-#1, -#2, and -
#3 AgAbs. These steps were followed by restriction digest and ligation of insert 
and plasmid backbone DNA, and the transformation of electrocompetent 
bacteria. 
 
 
4.2.1.1. Fusion of antibody heavy chain to EBNA3C segment 
 
The insert DNA was constructed by fusing the respective antibody heavy chain to 
the antigen segment (EBNA3C ORF bp 1 to 1023, 964 to 2016, 1957 to 2976). 
The B95.8 recombinant BAC (p2089) was used as a template to amplify the 
EBNA3C sequences. The antigen fragments were prolonged on their N-termini 
with an overlapping gene region that covers the C-terminus of the antibody 
heavy chain. Vice versa, the antibody heavy chain sequence was extended at its 
C-terminus with an overlapping gene region that covers the N-terminus of the 
antigen. These fragments were generated through PCR using oligonucleotides 
that carry the overlapping regions (10 to 20 bp). The stop codon of the antibody 
heavy chain sequence was removed to obtain a joint fusion transcript. On the 
contrary, a stop codon, a restriction site for (ind))) ȋͷ’ AAG CTT ͵’Ȍ and five 
additional bp (GCTCA) were inserted at the C-terminal region of the antigen. 
Upstream of the antibody heavy chain start codon (ATG), six random bp 
(TCGATT, at the very ͷ’ end) and a restriction site for EcoR) ȋͷ’ GAA TTC ͵’, right 
before the start codon) were inserted at the N-terminal end. The newly designed 
gene was cloned into the pRK5 eukaryotic expression vector through EcoRI and 
HindIII cloning sites.  
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For the construction of anti-human EBNA3C-AgAbs, EBNA3C segments were 
fused to the C-terminus of mouse IgG2a anti-human CD19, CD20, CD21, or CD22-
specific heavy chain sequences using overlap extension PCR cloning. The AgAbs 
were generated in a two-step process. First, antibody heavy chains and EBNA3C 
fragments were generated that both carried overlapping sequences to each other 
(Table 19, Figure 25). Second, both gene fragments were fused together using 
overlap extension PCR (Table 20, Figure 26), at which forward and reverse 
primers were added to the reaction mixture after ten PCR cycles in order to 
increase the amplification efficiency. The PCR protocol is described in 4.2.1.4.1. 
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PCR Product Core Flank Temp FW RV 
Ta 
(°C) 
Size 
(bp) 
1 
CH1- CH3 (mouse IgG2a anti-
human CD19) with C-flank to 
EBNA3C (1-1023) 
CH1-CH3 
(mouse 
IgG2a 
anti-
human 
CD19) 
EBNA3C  
(1-1023) 
B474 
1838 
1990 
67.4 1425 
2 
CH1- CH3 (mouse IgG2a anti-
human CD19) with C-flank to 
EBNA3C (964-2016) 
EBNA3C (964-
2016) 
2000 
3 
CH1- CH3 (mouse IgG2a anti-
human CD19) with C-flank to 
EBNA3C (1957-2976) 
EBNA3C 
(1957-2976) 
2002 
4 
CH1- CH3 (mouse IgG2a anti-
human CD20) with C-flank to 
EBNA3C (1-1023) 
CH1-CH3 
(mouse 
IgG2a 
anti-
human 
CD20) 
EBNA3C (1-
1023) 
B560 
1990 
5 
CH1- CH3 (mouse IgG2a anti-
human CD20) with C-flank to 
EBNA3C (964-2016) 
EBNA3C (964-
2016) 
2000 
6 
CH1- CH3 (mouse IgG2a anti-
human CD20) with C-flank to 
EBNA3C (1957-2976) 
EBNA3C 
(1957-2976) 
2002 
7 
CH1- CH3 (mouse IgG2a anti-
human CD21) with C-flank to 
EBNA3C (1-1023) 
CH1-CH3 
(mouse 
IgG2a 
anti-
human 
CD21) 
EBNA3C  
(1-1023) 
B233 
1990 
8 
CH1- CH3 (mouse IgG2a anti-
human CD21) with C-flank to 
EBNA3C (964-2016) 
EBNA3C (964-
2016) 
2000 
9 
CH1- CH3 (mouse IgG2a anti-
human CD21) with C-flank to 
EBNA3C (1957-2976) 
EBNA3C 
(1957-2976) 
2002 
10 
CH1- CH3 (mouse IgG2a anti-
human CD22) with C-flank to 
EBNA3C (1-1023) 
CH1-CH3 
(mouse 
IgG2a 
anti-
human 
CD22) 
EBNA3C  
(1-1023) 
B482 
1990 
11 
CH1- CH3 (mouse IgG2a anti-
human CD22) with C-flank to 
EBNA3C (964-2016) 
EBNA3C (964-
2016) 
2000 
12 
CH1- CH3 (mouse IgG2a anti-
human CD22) with C-flank to 
EBNA3C (1957-2976) 
EBNA3C 
(1957-2976) 
2002 
13 
EBNA3C (1-1023) with N-
flank to CH3 (mouse IgG2a) 
EBNA3C 
(1-1023) 
CH3 (mouse 
IgG2a) 
B338 
B_E 
1993 2006 56.3 1052 
14 
EBNA3C (964-2016) with N-
flank to CH3 (mouse IgG2a) 
EBNA3C 
(964-
2016) 
B338 
B_E 
2007 2014 56.4 1106 
15 
EBNA3C (1957-2976) with N-
flank to CH3 (mouse IgG2a) 
EBNA3C 
(1957-
2976) 
B338 
X_D 
2015 1998 52.4 1052 
Table 19: PCR setup for the construction of antibody heavy chain fragments and EBNA3C segments with 
overlapping sequences to each other for generating anti-human CD19, CD20, CD21, CD22 + EBNA3C-#1, 
-#2, -#3 AgAbs. Temp: template; FW: forward primer; RV: reverse primer; Ta: annealing temperature. 
Figure 25: Cloning scheme for the construction of antibody heavy 
chain fragments (anti-human CD19, CD20, CD21, CD22) and 
EBNA3C segments (#1, #2, #3). 
 MATERIAL AND METHODS  
 
 83 
 
 
 
 
 
PCR Product Temp FW RV 
Ta 
(°C) 
Size 
(bp) 
16 
CH1-CH3 (mouse IgG2a anti-
human CD19) + EBNA3C 
(1-1023) (B1202) 
1+13 
1838 
2006 56.3 2476 
17 
CH1-CH3 (mouse IgG2a anti-
human CD19) + EBNA3C 
(964-2016) (B1203) 
2+14 2014 53.6 2530 
18 
CH1-CH3 (mouse IgG2a anti-
human CD19 + EBNA3C 
(1957-2976) (B1204) 
3+15 1998 52.4 2476 
19 
CH1-CH3 (mouse IgG2a anti-
human CD20) + EBNA3C 
(1-1023) (B1205) 
4+13 2006 56.3 2470 
20 
CH1-CH3 (mouse IgG2a anti-
human CD20) + EBNA3C 
(964-2016) (B1206) 
5+14 2014 53.6 2524 
21 
CH1-CH3 (mouse IgG2a anti-
human CD20) + EBNA3C 
(1957-2976) (B1207) 
6+15 1998 52.4 2470 
22 
CH1-CH3 (mouse IgG2a anti-
human CD21) + EBNA3C 
(1-1023) (B1208) 
7+13 2006 56.3 2467 
23 
CH1-CH3 (mouse IgG2a anti-
human CD21) + EBNA3C 
(964-2016)  (B1209) 
8+14 2014 53.6 2521 
24 
CH1-CH3 (mouse IgG2a anti-
human CD21) + EBNA3C 
(1957-2976) (B1210) 
9+15 1998 52.4 2467 
25 
CH1-CH3 (mouse IgG2a anti-
human CD22) + EBNA3C 
(1-1023) (B1199) 
10+13 2006 56.3 2452 
26 
CH1-CH3 (mouse IgG2a anti-
human CD22) + EBNA3C 
(964-2016)  (B1200) 
11+14 2014 53.6 2506 
27 
CH1-CH3 (mouse IgG2a anti-
human CD22) + EBNA3C 
(1957-2976) (B1201) 
12+15 1998 52.4 2452 
Table 20: PCR setup for the construction of antibody heavy chains fused 
to EBNA3C segments for generating anti-human CD19, CD20, CD21, CD22 
+ EBNA3C-#1, -#2, -#3-AgAbs. Temp: template; FW: forward primer; RV: 
reverse primer; Ta: annealing temperature. 
Figure 26: Cloning scheme for the construction of antibody heavy chains (anti-human CD19, 
CD20, CD21, CD22) fused to EBNA3C segments (#1, #2, #3). 
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4.2.1.2. Restriction digest of insert DNA and plasmid backbone with subsequent 
DNA ligation 
 
Incorporation of insert DNA into plasmid backbone (B200) was performed 
through restriction digest and ligation. B200 is a pRK5 expression vector 
carrying the light chain gene for the anti-human CD21 antibody. The light chain 
gene is flanked by EcoRI and HindIII cloning sites, so that the gene was removed 
by restriction digest of the vector using the respective restriction enzymes. The 
insert DNA, which contains the gene of interest, was equally digested before it 
was ligated into the cut vector. Table 21 shows the setup for the digestion. 
 
Table 21: Setup for DNA digestion (B200) with EcoRI and HindIII. 
Reagents Plasmid backbone (B200) Insert DNA 
H2O 64 ɊL 24 ɊL 
Tango buffer (10 x) 20 ɊL 20 ɊL 
EcoRI (10 U/ɊL) 3 ɊL 3 ɊL 
HindIII (10 U/ɊL) 3 ɊL 3 ɊL 
DNA 10 ɊL (1 Ɋg/ɊL) = 10 Ɋg 50 ɊL (200 ng/ɊL) = 10 Ɋg 
 
The incubation was run at 37 °C for 3 h. The enzymes were then inactivated at 80 
°C for 20 min. The plasmid backbone was dephosphorylated through alkaline 
phosphatase (AP) by adding 79 ɊL H2O, 20 ɊL dephosphorylation buffer (10 ɊL), 
and 1 ɊL alkaline phosphatase (1 U/ɊL) to the digestion reaction (100 ɊL). The 
mix was incubated at 37 °C for 20 min followed by a temperature increase of 1 K 
per 30 sec until 65 °C was reached. The temperature was hold on 65 °C for 10 
min to inactivate the enzyme. The AP-treated plasmid DNA was purified by 
phenol extraction and butanol precipitation. 
T4 DNA ligase was used to connect the insert DNA to the plasmid backbone by 
forming covalent phosphodiester linkages. The amount of insert DNA required 
for the ligation with 100 ng digested AP-treated plasmid backbone was 
calculated by the following formula: 
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In a total volume of 10 ɊL, plasmid backbone (100 ng) and insert DNA 
(calculated) were mixed together with 1 ɊL of ligase buffer (10 x), and 0.8 ɊL T4 
ligase (4 U). The reaction was incubated at 16 °C over night. 
 
 
4.2.1.3. Transformation of electrocompetent bacteria and screening for 
recombinant clones 
 
The ligation product was introduced into chemically competent DH5Ƚ E. coli. 100 ɊL of freshly thawed bacteria were mixed with the total ligation reaction mix (10 ɊL) and incubated for 5 min on ice followed by 2 min on 42 °C. 2 mL of LB 
medium were added immediately afterwards, and the cells were incubated in an 
Ecotron shaker at 180 rpm and 37 °C for 30 min. 200 ɊL of the final cell 
suspension were plated on ampicillin (100 ɊL/mL)-containing LB agar plates 
and incubated for at least 16 h at 37 °C. 
Outgrown colonies were screened for the insertion of the correct plasmid. 
Random colonies were selected and plated on ampicillin (100 Ɋg/mL)-containing 
LB agar plates for overnight incubation at 37°C. The bacteria were scraped off 
the LB agar plates and plasmid preparation (mini-prep) was performed. The 
isolated DNA pellet was taken up in 30 ɊL TE buffer and digested enzymatically 
by using 3 ɊL DNA, 1 ɊL of the respective enzyme (10 U/ɊL, Thermo Fisher 
Scientific), buffer, and H2O (total volume of 20 ɊL). The digestion mixture was 
incubated for 1 h at 37 °C followed by enzyme inactivation. The sample was then 
loaded onto a 1 % agarose gel. Plasmids with the expected DNA banding patterns 
were sequenced. Transformed bacteria with the correct plasmid were selected 
for long-term storage in 10 % glycerol at -80 °C. 
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4.2.1.4. Other applied techniques 
 
4.2.1.4.1. PCR 
 
PCR application was performed in a total volume of 50 ɊL comprising 23.5 ɊL 
H2O, 10 ɊL Phusion HF buffer (5 x), 1 ɊL dNTPs (10 mM), 2.5 ɊL of 10 pmol/ɊL 
(25 pmol) forward primer, 2.5 ɊL of 10 pmol/ɊL (25 pmol) reverse primer, 10 ɊL 
template DNA (1 ng/ɊL), and 0.5 ɊL of 2 U/ɊL (1 U) Phusion® High Fidelity DNA 
Polymerase (New England BioLabs®). The reaction was performed in a PTC-200 
Peltier Thermo Cycler using the following program: 1) 98 °C for 30 sec; 2) 98 °C 
for 10 sec; 3) 45-72 °C for 30 sec; 4) 72 °C for 15-30s/kb; 5) repetition of cycle 
step 2) - 4) for 30 x; 6) 72 °C for 7 min; 7) 4 °C on hold. The annealing 
temperature (Ta) was determined by calculating the melting temperature (Tm) of 
primers (MacVector). 
 
 
4.2.1.4.2. DNA sequencing 
 
Sequence analysis of plasmids was performed by Eurofins Genomics. In a total 
volume of 15 ɊL, 1.35 Ɋg plasmid DNA was mixed with 15 pmol of a selected 
primer that covers the gene region of interest. Sequencing results were analyzed 
by using MacVector.  
 
 
4.2.1.4.3. Plasmid amplification and preparation  
 
Plasmid DNA was amplified in growing bacteria cultures and isolated by alkaline 
lysis. 
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4.2.1.4.3.1. Large scale (max-prep) 
 
200 mL LB medium (+ 100 Ɋg/mL ampicillin) was inoculated with bacteria from 
a glycerol stock and incubated in a 1 L shaking flask at 180 rpm (Ecotron shaker) 
for 16 h at 37 °C. Plasmid preparation was performed through alkaline lysis 
using the PureLinkTM HiPure Maxiprep Kit.  
 
 
4.2.1.4.3.2. Small scale (mini-prep) 
 
Ampicillin (100 Ɋg/mL)-containing LB agar plates were inoculated with bacteria 
and incubated at 37°C over night. The bacteria was scraped off the LB agar plates 
and resuspended into 1.5 mL tubes containing 200 ɊL TE buffer + 1 ɊL RNase A 
(10 mg/mL). 200 ɊL freshly prepared 1 % (v/v) SDS + 0.2 M NaOH (lysis buffer) 
was added to the reaction and the tube carefully inverted two to three times. The 
solution was incubated for 5 min at RT. The mixture was neutralized by adding 
200 ɊL of 3.1 M KAc (pH 5.5). The tube was carefully inverted two to three times, 
incubated for 10 min on ice and centrifuged at 13,000 rpm for 15 min in a 
HeraeusTM PicoTM 17 Microcentrifuge. The supernatant was transferred into a 
500 ɊL isopropanol-containing 1.5 mL tube and incubated for 10 min on ice. The 
tube was centrifuged at 13,000 rpm for 10 min. The DNA pellet was washed 
extensively with 1 mL EtOH (80 %) and the tube centrifuged at 13,000 rpm for 2 
min. EtOH was removed, the tube briefly centrifuged again, and the remained 
EtOH traces were completely taken off. 
 
 
4.2.2. Recruitment of CLL patient blood samples 
 
Heparinized peripheral blood samples (50 mL) were collected from twelve 
chemotherapy-naïve patients with CLL. Patients of all ages were allowed to take 
part in the study as long as all inclusion criteria were fulfilled and no exclusion 
criteria given. Inclusion criteria implicated that (1) patient is diagnosed with 
CLL, (2) patient is chemotherapy-naïve, (3) patient is willing to give written 
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informed consent. Excluded from this study were (1) patients pre-treated with 
chemotherapy or chemoimmunotherapy or/and (2) patients suffering from 
anemia of any reason. CLL patients were recruited at the participating clinical side ȋDepartment of ǲ)nnere Medizin Vǳ, Prof. Dr. med. Dreger, 
Universitätsklinikum Heidelberg). The study participation required a visit at the 
clinical center. After study information by a clinical investigator, all participants 
provided informed written consent in compliance with the Declaration of 
Helsinki [265]. The visit and sample collections were scheduled along with 
routine visits and blood testing, which are needed as part of the regular disease 
monitoring. Thus, no extra study-related visit or punctures were required for the 
purpose of this study. Ethical permission was obtained from the Ethical Review 
Committee of the Medical Faculty Heidelberg (Ethikkommission der 
Medizinischen Fakultät Heidelberg S603/2015). Mononuclear cell fractions were 
isolated from blood of healthy donors and used as controls. The data of patients 
and volunteers were pseudonymised. 
 
 
4.2.3. Tissue culturing 
 
4.2.3.1. Preparation of human blood serum 
 
Human serum (HS) was utilized as a medium supplement to enable optimal 
growth of human T cells. HS was prepared from freshly drawn whole blood of 
consented volunteers, usually two donors at a time. The blood was incubated in 
an upright position at RT for > 1 h to allow clotting. The clotted blood samples 
were thoroughly shaken by hand. The procedure was repeated three to four 
times every 20 min. The tubes were then centrifuged in a Heraeus Megafuge 1.0 
centrifuge at 1,600 rpm for 15 min (without brake). The supernatants of sera 
were carefully aspirated and transferred into 50 mL falcon tubes. The sera were 
centrifuged again at 2,000 rpm for 5 min to remove the turbidity, which mainly 
derives from red blood cells and insoluble matter. For complement degradation, 
the serum was heat-inactivated at 56 °C during which it was swirled every 10 
min until 30 min had elapsed. The prepared serum of two donors was pooled. 
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Ethical approval to use serum from voluntary donors was obtained from the 
Ethikkommission of the Medizinische Fakultät Heidelberg (S-36/2011). 
 
 
4.2.3.2. Isolation of PBMCs 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from venous blood of 
CLL patients or healthy donors by density gradient centrifugation using Ficoll-
PaqueTM Plus. 50 mL blood was diluted with 75 mL of 4 mM EDTA-containing 
PBS in a 250 mL centrifuge tube, underlaid with 63 mL Ficoll-Paque and 
centrifuged in a Heraeus Multifuge 3L centrifuge at 1,800 rpm for 30 min ȋwithout brakeȌ. The white ǲbuffy coatǳ layer, which includes the PBMC fraction, 
was transferred into a 50 mL falcon tube and washed three times with RPMI 
Medium 1640 by centrifuging at 1,600, 1,400, and 1,200 rpm for 10 min, 
respectively. PBMCs were counted and diluted to an appropriate concentration 
in T cell medium. Cells of CLL patients were taken up in AIM V® Medium 
supplemented with 10 % DMSO and cryopreserved in liquid nitrogen. PBMCs 
were thawed quickly at 37 °C using a water bath, washed and treated with 
RNase. Thereby, 10 U of RNase-free DNase I was applied to 5 x 106 PBMC/mL at 
37 °C for 1 h to prevent cell clumping typically observed after PBMC thawing. 
PBMCs used as feeder cells for T cell culture maintenance were isolated from red 
cell concentrate donations that were obtained from the ǲ)nstitut f“r Klinische Transfusionsmedizin und Zelltherapie ȋ)KTZȌ (eidelberg gemeinn“tzige Gmb(ǳ. 
 
 
4.2.3.3. Generation of LCLs 
 
B cells were isolated from PBMCs by using magnetic CD19 beads (DynabeadsTM 
CD19 Pan B / DETACHaBEADTM CDͳͻȌ according to the manufacturer’s 
instructions. For the generation of LCLs from healthy donors and CLL patients, 2 
x 105 and 5 x 106 B cells were transformed with the B95.8 strain of EBV at a 
multiplicity of infection (MOI) of 5 and 2 viruses per cell, respectively for 2 h at 
RT. 
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LCLs were cultured in RPMI Medium 1640 supplemented with 10 % HS.  
 
 
4.2.3.4. Recombinant expression of antibodies 
 
AgAbs and native Abs were recombinantly expressed in HEK293 cells after 
transient transfection with plasmid DNA using PEI. Plasmids encoding antibody 
heavy and light chains were transfected at a ratio of 2:1. Briefly, 5 x 106 HEK293 
cells in 10 mL RPMI Medium 1640 supplemented with 2 % FBS were seeded on 
Petri dishes (60 cm2). The medium was replaced with 10 mL fresh RPMI Medium 
1640 (without FBS) on the next day. Plasmid DNA ȋͳͳ.ʹͷ Ɋg of heavy and light 
chain antibody-containing plasmid, respectively) and PEI (͵.Ͷ ɊL of 10 mg/mL) 
were mixed in ͹ͷͲ ɊL Opti-MEM® I, incubated at RT for 20 min and gently added 
to the cells. After incubating the cells for 5 h at 37 °C, the medium was removed 
and replaced by FreeStyleTM 293 Expression Medium (gibco®). The antibody-
containing supernatant was harvested after 72 h at 37 °C, centrifuged and 
filtered through a 0.22 Ɋm pore size filter (Merck Millipore). The antibody 
solution was concentrated using MWCO 10,000 Dalton centrifugal filters 
(Vivaspin® 20). The concentrate was sterile-filtered using Ultrafree®-CL 
centrifugal devices (Merck Millipore). 
 
 
4.2.3.5. Quantification of mouse IgG2a anti-human AgAbs and mAbs  
 
AgAbs and mAbs produced in HEK293 cells were quantified using human IgG2a 
ELISA assay. EIA/RIA 1 x 8 StripwellTM 96 well plates (Corning) were coated with ͷͲ ɊL capture antibody ȋAffiniPure Goat Anti-Mouse IgG + IgM (H + L), Jackson )mmunoResearch LabȌ ȋͷ Ɋg/mLȌ per well. Uncoated sites of the solid support 
were blocked with a 2 % FBS-containing PBS solution (300 ɊL per well). The 
wells were washed at every step with 0.05 % Tween-20 PBS (300 ɊL per well, 
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three time). The test samples were added along with the IgG standard (50 ɊL per 
well), a commercial mouse IgG2a antibody (anti-human CD21, THB-5, Santa 
Cruz) that was diluted to 4000, 2000, 1000, 500, 250, 125, 62.5, and 0 pg/mL for 
45 min. As detection antibody, anti-mouse IgG-HRP conjugate (Promega, 50 ɊL of Ͳ.ͷ Ɋg/mL) was applied to each well. After 45 min of incubation, Substrate 
Reagent A and B (2:1) of the BD OptEIATM TMB substrate reagent set were mixed 
and 50 ɊL added to each well. 50 ɊL of 2N H2SO4 were added to stop the reaction. 
The absorbance was measured at 450 nm (wavelength correction at 540 nm) 
using a microplate photometer (Multiskan Ex by Thermo Electron Corporation). 
 
 
4.2.3.6. Ex vivo expansion of EBNA3C-specific CD4+ T cells 
 
CD4+ T cells specific for EBNA3C were ex vivo expanded from PBMCs through 
biweekly stimulation with all twelve EBNA3C-AgAbs (anti-CD19, -CD21, -CD20, -
CD22 antibodies conjugated with EBNA3C-#1, -#2, and -#3, respectively). 5 x 106 
PBMCs were cultured in 2 mL T cell medium (without IL-2) supplemented with 
increasing concentrations of EBNA3C-AgAbs (1 - 5 ng/mL per EBNA3C-AgAb) 
using 24 well plates (TPP®). After 2 weeks, 5 x 106 of fresh (or freshly thawed) 
autologous PBMCs were treated with the same AgAb concentrations (for 16 h at 
37 °C) as before, irradiated (40 Gy) and mixed with 1x106 c of PBMCs from the 
foregoing cycle in 2mL AIM V® Medium with IL-2 (10 U/mL). The same 
procedure was applied every two weeks using 2 x 106 of fresh (or freshly 
thawed) autologous PBMCs in week 4, 6, 8, and 10. From week 12, 2 x 105 
autologous LCLs were pulsed with EBNA3C-AgAbs (10 ng per AgAb), irradiated 
(80 Gy) and mixed with irradiated PBMCs (1 x 106) from unrelated buffy coats 
that were used as feeder cells. In some cases, co-expanded CD8+ T cells were 
depleted by using CD8a PE antibodies and PE MicroBeads (Miltenyi Biotec) 
according to the manufacturer’s instructions. 
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4.2.4. Analysis 
 
4.2.4.1. Western blotting 
 
The expression of mAbs and AgAbs produced in HEK293 cells was assessed 
through Western blotting. 1 to 10 ng of the product were diluted in 4 x protein loading buffer ȋPLBȌ without Ⱦ-mercaptoethanol (non-reducing) (20 ɊL total). 
For the analysis of reduced Igs, 1 x 106 production cells were resolved in 1 mL 
RIPA buffer containing 1 ɊL protease inhibitor (1000 x, Sigma-Aldrich) and 
sonicated (Sonopulus HD2070, Bandelin Electronics) in ice-cold water. 15 ɊL of 
lysate were mixed with 5 ɊL of 4 x PLB containing Ⱦ-mercaptoethanol. All 
samples were boiled at 95 °C for 10 min. Non-reduced and reduced samples 
were separated on a biphasic SDS-polyacrylamide gel with stacking and 
separating phase (7.5 % or 12.5 %, respectively). As protein standard, 3 ɊL of 
PageRulerTM Prestained Protein Ladder (10 – 180 kDa) or SpectraTM Multicolor 
High Range Protein Ladder (40 – 300 kDa) were loaded. The samples were 
electroblotted onto a nitrocellulose membrane (Protran®), which was then 
blocked by using 3 % skimmed milk buffer (SMB) for 1 h at room temperature. 
Afterwards, goat anti-mouse IgG-HRP detection antibody (Promega) was applied 
(1:30,000 in SMB) for 1 h at room temperature. The membrane was washed 3 x 
20 min with PBS-T, incubated in 5 mL Western Lightning® Plus-ECL reagent 
(PerkinElmer) for 1 min and exposed to an AmershamTM HyperfilmTM ECL film. 
 
 
4.2.4.2. Flow cytometry analysis 
 
5 x 105 target cells were incubated with fluorochrome-conjugated antibodies in ͳͲͲ ɊL FACS buffer for ͵Ͳ min on ice and in the dark. Cells were washed twice 
with 1 mL of the same buffer, resuspended in 500 ɊL of it and filtered through a 
5 mL polystyrene round-bottom tube with cell-strainer cap (12 x 75 mm). The 
fluorescence distribution was analyzed on BD FACSCaliburTM. In multicolor flow 
cytometry analysis, spectral overlap was corrected by compensation with single 
fluorochrome-stained cell samples. Viable lymphocytes were gated and 10,000 
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events per sample were recorded using CellQuest. Flow cytometry data was 
analyzed using FlowJo V.10.1. Fluorochrome-conjugated antibodies used for flow 
cytometry experiments were directed against CD19, CD5, CD3, CD4, CD8a, and 
HLA class II molecules (HLA-DP, -DQ, -DR). Non-conjugated primary antibodies 
used were directed against CD19, CD20, CD21, and CD22, and were produced in 
HEK293 cells (isotype: mouse IgG2a, 250 ng). As secondary antibody, anti-mouse 
IgG2a conjugated with PE was used. Commercial antibody isotype controls 
(mouse IgG1 or IgG2a) were applied in the analyses to exclude non-specific Fc 
domain binding to target cells. A detailed description of the utilized commercial 
antibodies is given in Table 8. 
 
 
4.2.4.3. T cell function analysis 
 
4.2.4.3.1. IFN-γ release 
 
T cell activation induced by the recognition of antigens presented on APCs was 
assessed through the release of IFN-γ as surrogate marker. 5 x 104 target cells 
(LCLs, isolated CLL cells, or CLL cells in PBMC pool) were incubated with native 
antibodies, EBNA3C-AgAbs, peptides, or mock medium (RPMI 1640) in a U-
bottomed well plate for 8 h at 37 °C. Autologous T cells were added at various 
E:T ratios for 16 h at 37°C . IFN-γ released into the supernatants was quantiﬁed 
using IFN-γ ELISA (Mabtech) according to the manufacturer’s instructions. After 
the last round of washing, 100 ɊL of mixed Substrate Reagent A and B (2:1) of 
the BD OptEIATM TMB substrate reagent set were given to each well. The 
reaction was stopped with 50 ɊL of 2N H2SO4. The absorbance was immediately 
measured at 450 nm (wavelength correction at 540 nm) using the Multiskan Ex 
microplate photometer. 
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4.2.4.3.2. GrB release 
 
The cytotoxic potential of T cells was assessed by their ability to release GrB 
upon activation. Experiments were set up as for IFN-γ release assays described 
in 4.2.4.3.1. GrB release was quantified using a GrB ELISA kit (Mabtech) according to the manufacturer’s manual instructions. After the last round of 
washing, 100 ɊL of mixed Substrate Reagent A and B (2:1) of the BD OptEIATM 
TMB substrate reagent set were given to each well. The reaction was stopped 
with 50 ɊL of 2N H2SO4. The absorbance was immediately measured at 450 nm 
(wavelength correction at 540 nm) using the Multiskan Ex microplate 
photometer. 
 
 
4.2.4.3.3. Expression of CD107a 
 
The expression of CD107a on T cells was assessed upon stimulation with 2 x 105 
target cells incubated with mock medium (RPMI 1640) only, native antibodies, 
or EBNA3C-AgAbs (200 ng) for 16 h at 37°C. CD4+ T cells were added at E:T = 
3:1. Anti-CD107a conjugated with FITC was immediately added to the co-culture 
to prevent CD107a signal loss through internalization of the receptor. Cells were 
washed and resuspended in 100 ɊL FACS buffer containing anti-CD4 PE-Cy5, 
incubated for 30 min on ice in the dark and analyzed by flow cytometry. Data 
were recorded and analyzed as described in 4.2.4.2. 
 
 
4.2.4.3.4. Calcein release 
  
The ability of effector T cells to lyse target cells treated with AgAbs was 
determined in a CAM release assay, as previously described [266]. RPMI Medium 
1640 without phenol red (gibco®) was used at all steps. Target cells (5 x 104 per 
test) were treated with native antibodies or AgAbs (50 ng) for 16 hours at 37 °C. 
After washing and staining with CAM ȋͷ ɊMȌ for ͵Ͳ min at 37 °C, these cells were 
distributed in a round U-bottom well plate. For the calculation of percentage cell 
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lysis, cells were treated with 1 % Triton-X 100 or mock medium in order to 
determine maximum or spontaneous release, respectively. Effector T cells were 
added at E:T ratios ranging from 1:1 to 30:1. In some cases, T cells were 
pretreated with the perforin inhibitor CMA (50 nM) at 37 °C for 90 min [231]. 
Maximum and spontaneous release controls did not receive any T cells. The final 
volume of each well was 200 ɊL. Supernatants were harvested after 3 hours and 
the degree of cell lysis was determined by the amount of released calcein, which 
was measured by a fluorescence plate reader (Wallac Victor3 Multilabel Counter, 
emission/excitation = 535 nm/485 nm for 1 sec). Specific lysis was calculated as 
follows: specific lysis (%) = (experimental calcein release – spontaneous calcein 
release) / (maximum calcein release – spontaneous calcein release) x 100 %. 
 
 
4.2.4.4. Statistical analysis 
 
Statistical analyses were performed using SPSS. Graphs were plotted by 
GraphPad. To investigate the main and interaction effects of data presented in 
Figure 21e and 24c, repeated-measures ANOVAs were conducted. Two-sided t-
tests were used for post-hoc analyses. Pairwise comparisons were Bonferroni-
corrected. For all analyses, p-values lower than .05 were considered significant.  
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mCMV murine cytomegalovirus 
MHC major histocompatibility complex 
MoAHu mouse anti-human 
MoAMo mouse anti-mouse 
MOI multiplicity of infection 
MWCO Molecular weight cut-off 
NHL non-(odgkin’s lymphoma 
NPC nasopharyngeal carcinoma 
ORF open reading frame 
OS overall survival 
PAGE polyacrylamide gel 
PBMC peripheral blood mononuclear cell 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PE phycoerythrin 
PE-Cy5 phycoerythrin-cyanin 5 
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PFS progression-free survival 
PLB protein loading buffer 
PTLD 
post-transplantation 
lymphoproliferative disorder 
SMB skimmed milk buffer 
svFv single-chain variable fragment 
Ta annealing temperature 
TAA tumor-associated antigen 
TCR T cell receptor 
TEMED tetramethylethylenediamine 
TGF-Ⱦ tumor growth factor beta 
Th T helper 
TIL tumor-infiltrating lymphocyte 
Tm melting temperature 
TNF-Ƚ tumor necrosis factor alpha  
V-ATPase vacuolar type H+-ATPase 
V(D)J variable, diversity, joining 
WHO World Health Organization 
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